Document:

EX-10.7

 Exhibit 10.7 

A&R Services and Collaboration Agreement 

Confidential 
 Amended and
Restated Services and Collaboration Agreement 
 by and between 

ModernaTx, Inc., 
 and

 AstraZeneca AB 

June 15, 2018 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
 Table of Contents 
  

									
	 	  	Page	 
		
	 1.  Definitions
	  	 	2	 
		
	 2.  Services Program
	  	 	13	 
				
	 	 	 2.1.
	 	 General
	  	13	 
				
	 	 	 2.2.
	 	 Research Polypeptide Selection
	  	13	 
				
	 	 	 2.3.
	 	 Services Plan
	  	14	 
				
	 	 	 2.4.
	 	 Services Program Term; Development Pool Services
	  	15	 
				
	 	 	 2.5.
	 	 Ownership of Technology
	  	16	 
				
	 	 	 2.6.
	 	 Third Party In-Licenses
	  	17	 
				
	 	 	 2.7.
	 	 Moderna’s Non-Performance
	  	18	 
				
	 	 	 2.8.
	 	 Services Program Expenses
	  	18	 
				
	 	 	 2.9.
	 	 Services Program Records, Reports and Materials
	  	19	 
				
	 	 	 2.10.
	 	 Permitted Subcontracting and Sublicensing
	  	20	 
				
	 	 	 2.11.
	 	 Regulatory Activities
	  	20	 
				
	 	 	 2.12.
	 	 Applicable Laws and Bioethics Policy
	  	20	 
		
	 3.  Governance
	  	 	20	 
				
	 	 	 3.1.
	 	 Services Program Management
	  	20	 
				
	 	 	 3.2.
	 	 Joint Steering Committee
	  	21	 
		
	 4.  Manufacturing
	  	 	23	 
				
	 	 	 4.1.
	 	 General Obligation to Supply
	  	23	 
				
	 	 	 4.2.
	 	 Non-cGMP Supply for Services Program
	  	24	 
				
	 	 	 4.3.
	 	 cGMP Supply Agreements
	  	24	 
				
	 	 	 4.4.
	 	 [***]
	  	25	 
				
	 	 	 4.5.
	 	 Technology Transfer
	  	25	 

  
 i 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

									
				
	 	 	 4.6.
	 	 [***]
	  	26	 
				
	 	 	 4.7.
	 	 Triggering Events
	  	26	 
				
	 	 	 4.8.
	 	 Force Majeure
	  	26	 
				
	 	 	 4.9.
	 	 Manufacturing Know-How Confidentiality
	  	26	 
				
	 	 	 4.10.
	 	 Preparation of CMC Section and DMF
	  	27	 
		
	 5.  Regulatory Responsibilities
	  	 	27	 
				
	 	 	 5.1
	 	 In General
	  	27	 
				
	 	 	 5.2
	 	 Regulatory Filings
	  	27	 
				
	 	 	 5.3
	 	 Interactions with Regulatory Authorities
	  	27	 
				
	 	 	 5.4
	 	 Moderna Regulatory Responsibilities Related to Manufacture
	  	27	 
				
	 	 	 5.5
	 	 Cooperation
	  	28	 
		
	 6.  Payment
	  	 	28	 
				
	 	 	 6.1.
	 	 Up-Front Payment
	  	28	 
				
	 	 	 6.2.
	 	 Reports; Payments
	  	28	 
				
	 	 	 6.3.
	 	 Records and Audits
	  	28	 
		
	 7.  Confidentiality
	  	 	29	 
				
	 	 	 7.1.
	 	 Confidential Information
	  	29	 
				
	 	 	 7.2.
	 	 Publications
	  	30	 
				
	 	 	 7.3.
	 	 Terms of this Agreement; Publicity
	  	31	 
				
	 	 	 7.4.
	 	 Relationship to the Confidentiality Agreement
	  	32	 
		
	 8.  Representations and Warranties; Limitations of Liability;
Indemnification
	  	 	32	 
				
	 	 	 8.1.
	 	 Representations and Warranties of Each Party
	  	32	 
				
	 	 	 8.2.
	 	 Disclaimers
	  	33	 
				
	 	 	 8.3.
	 	 No Consequential Damages
	  	33	 
				
	 	 	 8.4.
	 	 Performance by Others
	  	34	 

  
 ii 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

							
				
	 	 	 8.5.
	 	 Indemnification
	  	34
				
	 	 	 8.6.
	 	 Insurance
	  	36
		
	 9.  Term and Termination
	  	36
				
	 	 	 9.1.
	 	 Term
	  	36
				
	 	 	 9.2.
	 	 Termination by Moderna for Breach
	  	36
				
	 	 	 9.3.
	 	 Termination by AstraZeneca
	  	37
				
	 	 	 9.4.
	 	 Alternative to Termination
	  	37
				
	 	 	 9.5.
	 	 Effects of Termination or Expiration
	  	38
				
	 	 	 9.6.
	 	 Survival
	  	38
				
	 	 	 9.7.
	 	 Integrated Agreements
	  	39
		
	 10.  Tax Treatment of Agreement
	  	39
				
	 	 	 10.1
	 	 [***]
	  	39
				
	 	 	 10.2
	 	 [***]
	  	39
				
	 	 	 10.3
	 	 Indirect Taxes
	  	39
				
	 	 	 10.4
	 	 Import Duties
	  	39
		
	 11.  General Provisions
	  	39
				
	 	 	 11.1.
	 	 Dispute Resolution for the Transaction Agreements
	  	39
				
	 	 	 11.2.
	 	 Cumulative Remedies and Irreparable Harm
	  	40
				
	 	 	 11.3.
	 	 Business Combination
	  	41
				
	 	 	 11.4.
	 	 Anti-Bribery and Corruption Compliance
	  	41
				
	 	 	 11.5.
	 	 Relationship of Parties
	  	42
				
	 	 	 11.6.
	 	 Compliance with Law
	  	42
				
	 	 	 11.7.
	 	 Data Privacy
	  	42
				
	 	 	 11.8.
	 	 Force Majeure
	  	43
				
	 	 	 11.9.
	 	 Governing Law
	  	43

  
 iii 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

									
	    	 	11.10.	 	 Counterparts; Facsimiles
	  	 	43	 
				
		 	11.11.	 	 Headings
	  	 	43	 
				
		 	11.12.	 	 Waiver of Rule of Construction
	  	 	43	 
				
		 	11.13.	 	 Interpretation
	  	 	43	 
				
		 	11.14.	 	 Binding Effect
	  	 	43	 
				
		 	11.15.	 	 Assignment
	  	 	44	 
				
		 	11.16.	 	 Notices
	  	 	44	 
				
		 	11.17.	 	 Right to Set-Off
	  	 	45	 
				
		 	11.18.	 	 Amendment and Waiver
	  	 	45	 
				
		 	11.19.	 	 HSR Act Filings
	  	 	45	 
				
		 	11.20.	 	 Severability
	  	 	45	 
				
		 	11.21.	 	 Entire Agreement
	  	 	45	 

  
 iv 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 List of Exhibits and Schedules 

 

			
	Exhibit A-1	  	non-cGMP Moderna mRNA API Supply Terms
	Exhibit A-2	  	cGMP Moderna mRNA API Supply Terms
		
	Schedule 1.34	  	Continuation Criteria
	Schedule 1.100	  	Moderna Patents as of the Signing Date
	Schedule 2.12	  	AstraZeneca Bioethics Policy
		
	Appendix A:	  	Nominated Research Polypeptides

  

 Amended and Restated Services and Collaboration Agreement 

This Services and Collaboration Agreement (this “Agreement”), dated as of June 15, 2018 (the “Amendment
Effective Date”), is made by and between ModernaTx, Inc., a Delaware corporation (“Moderna”) and AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with offices at
SE-431 83 Mölndal, Sweden (“AstraZeneca”). Each of Moderna and AstraZeneca may be referred to herein as a “Party” or together as the “Parties.” 

WHEREAS, Moderna has developed expertise and technology useful for the discovery, development, Manufacture, characterization, or use of
therapeutic products that function using mRNA; 
 WHEREAS, AstraZeneca is a biopharmaceutical company focused on identifying, Developing and
Commercializing innovative therapeutic products; 
 WHEREAS, Moderna has provided certain Development and Manufacturing services under the
Services and Collaboration Agreement made as of March 20, 2013 as amended on August 23, 2013, December 5, 2014, December 2, 2016, April 10, 2018 and May 14, 2018 (the “Original Services and Collaboration
Agreement”), and the Parties have otherwise collaborated on the evaluation of mRNA Constructs [***] Polypeptides for certain Targets for the purpose of assisting AstraZeneca in determining whether or not to exercise its option rights under
the original Option Agreement of the same date as amended on January 10, 2015, April 10, 2018 and May 14, 2018 with respect to certain mRNA Constructs, Polypeptides and Targets (the “Original Option Agreement” and
together, the “Original Agreements”); 
 WHEREAS, under the Original Agreements AstraZeneca exercised one of its Options
and nominated an Optioned Product Candidate for the Target VEGF-A [***]; 
 WHEREAS, the Parties
wish to extend the Service Program with respect to certain Targets subject to revised terms; 
 WHEREAS, the Parties wish to amend and
restate the Original Services and Collaboration Agreement as set forth herein. [***]; and 
 WHEREAS, concurrent with the execution of this
Agreement, AstraZeneca and Moderna are entering into an Amended and Restated Option Agreement (the “A&R Option Agreement”), pursuant to which AstraZeneca will have an exclusive option (but not obligation) to purchase the rights
to certain mRNA Constructs [***] up to [***] Polypeptides for certain Targets ([***] having already been purchased under the Original Option Agreement). 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the amount and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

1.    Definitions. 
 The
following terms and their correlatives will have the following meanings. Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Transaction Agreements. 

1.1.    “A&R Option Agreement” has the meaning set forth in Recitals. 

1.2.     “Affiliate” of a Person means any other
Person which (directly or indirectly) is controlled by, controls or is under common control with such Person. For the purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled
by” and “under common control with”) as used with respect to a Person means (a) in the case of a corporation, direct or indirect ownership of voting securities entitled to cast more than fifty percent (50%) of the votes in the
election of directors or (b) in the case of a non-corporate Person, direct or indirect ownership of more than fifty percent (50%) of the equity interests with the power to direct the management and
policies of such entity. 
 1.3.    “Agreement” has the meaning set forth in Recitals. 

1.4.    “Anti-Corruption Law” has the meaning set forth in Section 11.4(b). 

1.5.    “Approved Manufacturer” has the meaning set forth in paragraph 3(k) of Exhibit A-1 or in Exhibit A-2. 

1.6.    “AstraZeneca” has the meaning set forth in Recitals. 

1.7.    “AstraZeneca Anticipated Requirements” has the meaning set forth in Section 4.4(a). 

1.8.    “AstraZeneca Background Know-How” means any and all Know-How Controlled by AstraZeneca or its Affiliates as of the Signing Date or as to which AstraZeneca or its Affiliates obtains Control during the Services Program Term or until such time as no more Development
Pool Services are performed, if later, that [***] excluding any AstraZeneca Collaboration Know-How. 

1.9.    “AstraZeneca Background Patents” means those Patents that are Controlled by AstraZeneca or its
Affiliates as of the Signing Date or as to which AstraZeneca or its Affiliates obtains Control during the Services Program Term or until such time as no more Development Pool Services are performed, if later, that [***]. 

1.10.    “AstraZeneca Background Technology” means the AstraZeneca Background Know-How and the AstraZeneca Background Patents. 
 1.11.    “AstraZeneca
Collaboration Know-How” means any and all Collaboration Know-How owned by AstraZeneca [***], including AstraZeneca’s right and interest in any Joint
Collaboration Know-How. 
 1.12.    “AstraZeneca Collaboration
Patents” means any and all Patents that claim any of the AstraZeneca Collaboration Know-How, including AstraZeneca’s right and interest in any Joint Patents. 

  
 2 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.13.    “AstraZeneca Collaboration Technology” means
the AstraZeneca Collaboration Know-How and the AstraZeneca Collaboration Patents. For clarity, all AstraZeneca Collaboration Technology will be “Controlled” by AstraZeneca for purposes of this
Agreement. 
 1.14.    “AstraZeneca Indemnitees” has the meaning set forth in Section 8.5(b). 

1.15.    “AstraZeneca In-License” has the meaning set forth in
Section 2.6(e)(i). 
 1.16.    “AstraZeneca [***] Technology” means any Know-How, Materials and Patents [***]). 
 1.17.    “AstraZeneca [***]
Technology” has the meaning set forth in Section 2.5(a)(i). 
 1.18.    “AstraZeneca Program
Director” has the meaning set forth in Section 3.1. 
 1.19.    “AstraZeneca Technology”
means collectively, AstraZeneca Background Technology and AstraZeneca Collaboration Technology (including any AstraZeneca [***] Technology). 

1.20.     “BLA” means a Biologics License Application filed with the FDA or an equivalent application to
any Regulatory Authority (including an NDA or its foreign equivalent) requesting Regulatory Approval for a new product, including for Product. 

1.21.    “Business Combination” means with respect to a Party, any of the following events: (a) any
Third Party (or group of Third Parties acting in concert) acquires (including by way of a tender or exchange offer or issuance by such Party), directly or indirectly, beneficial ownership or a right to acquire beneficial ownership of shares of such
Party representing fifty percent (50%) or more of the voting shares (where voting refers to being entitled to vote for the election of directors) then outstanding of such Party; (b) such Party consolidates with or merges into another
corporation or entity which is a Third Party, or any corporation or entity which is a Third Party consolidates with or merges into such Party, in either event pursuant to a transaction in which more than fifty percent (50%) of the voting shares of
the acquiring or resulting entity outstanding immediately after such consolidation or merger is not held by the holders of the outstanding voting shares of such Party immediately preceding such consolidation or merger; or (c) such Party sells,
transfers, leases or otherwise disposes of all or substantially all of its assets to a Third Party. 

1.22.    “Business Day” means any day other than a Saturday or Sunday on which banking institutions in
New York, US, London, England, and Stockholm, Sweden are open for business. 
 1.23.    “Calendar
Quarter” means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

1.24.     “cGMP” means current good manufacturing practices and regulatory requirements, as specified in
regulations promulgated from time to time by the FDA for the manufacture and testing of pharmaceutical products. 

1.25.    “CMC” has the meaning set forth in Section 5.4. 

  
 3 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.26.    “Collaboration
Know-How” means all Know-How and Materials conceived, discovered, developed or otherwise made by or on behalf a particular Party or any of its Affiliates and
Sublicensees (solely or jointly by or on behalf a particular Party or any of its Affiliates and Sublicensees) in the course of performing activities under or in connection with [***], but excluding [***], AstraZeneca [***] Technology. 

1.27.    “Collaboration mRNA Constructs” [***] means [***]. 

1.28.    “Collaboration Patents” means any and all Patents that claim any of the Collaboration Know-How. 
 1.29.    “Collaboration Technology” means the
Collaboration Know-How and Collaboration Patents. 

1.30.    “Commercialization” means (a) any and all activities directed to the Manufacturing,
marketing, detailing, promotion and securing of reimbursement of a product after Regulatory Approval has been obtained (including making, having made, using, importing, selling and offering for sale such product), and will include post-approval
clinical studies, post-launch marketing, promoting, detailing, marketing research, distributing, customer service, administering commercially selling, having sold or otherwise disposing or offering to dispose of such product, importing, exporting or
transporting such product for commercial sale, and all regulatory compliance with respect to the foregoing, and (b) otherwise marketing, selling or exploiting commercially a product. 

1.31.    “Commercially Reasonable Efforts” means the carrying out of obligations by a Party [***], using
that level of efforts and resources which [***]. 
 1.32.    “Confidential Information” has the meaning
set forth in Section 7.1(a). 
 1.33.    “Confidentiality Agreement” means the Reciprocal
Confidentiality Agreement between the Parties made effective as of October 30, 2012. 

1.34.    “Continuation Criteria” means, as the context requires, [***] as described in [***]. 

1.35.    “Contract Year” means each three hundred sixty five (365) or three hundred sixty six
(366) day (as applicable) period beginning on the Implementation Date or an anniversary of the Implementation Date, as applicable, occurring prior to the end of the Term. 

1.36.    “Control” or “Controlled” means, with respect to any Know-How, Material or Patent, the possession (whether by ownership, license or sublicense, other than by [***]) by a Party of the ability to assign or grant to the other Party the licenses, sublicenses or rights to
access and use such Know-How, Material or Patent as provided for in the Transaction Agreements, without requiring the payment of any royalties or other consideration therefor or violating the terms of any
agreement or other arrangement with any Third Party in existence as of the time such Party would be required hereunder to grant such license, sublicense, or rights of access and use. For clarity, Know-How,
Materials and Patents (a) that are [***], and (b) Know-How, Materials and Patents that are licensed to Moderna pursuant to a Moderna In-License are not
“Controlled” for purposes of the Transaction Agreements unless and only after such Moderna In-License is converted into a Moderna Collaboration In-License
pursuant to Section 2.6(c) and [***] For clarity, [***]. 

  
 4 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.37.    “Cover” or “Covered” or
“Covering”, with reference to (a) a Patent, means [***], and (b) Know-How, means [***]. 

1.38.    “[***] Criteria” means the [***] criteria for selection of a lead candidate suitable for [***],
such criteria to be specified [***] in the Services Plan for each Research Polypeptide. 
 1.39.    
“Development” means research and preclinical and clinical drug development activities, including: research, test method development and stability testing, toxicology, formulation, optimization, modification, enhancement,
improvement, process development, qualification and validation, Manufacture scale-up, development-stage Manufacturing, quality assurance/quality control, holding/keeping (whether for disposal or otherwise),
clinical studies, statistical analysis and report writing, the preparation and submission of Regulatory Filings, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or
required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval, and “Develop”, “Developed” and “Developing” will have corresponding meanings. 

1.40.    “Development Polypeptide” has the meaning set forth in the A&R Option Agreement. 

1.41.    “Development Pool Services” has the meaning set forth in Section 2.4(b). 

1.42.    “Disclosing Party” has the meaning set forth in Section 7.1(a). 

1.43.    “Discontinued Polypeptide” means any Research Polypeptide or Development Polypeptide that has by
any of the terms of the Transaction Agreements or the Original Agreements become a “Discontinued Polypeptide”. 

1.44.    “Discontinued Product Candidate” means any Collaboration mRNA Construct, Product Candidate or
Development Pool Candidate that has by any of the terms of the Transaction Agreements or the Original Agreements become a “Discontinued Product Candidate”. 

1.45.    “Discontinued Target” means any Research Target that has by any of the terms of the Transaction
Agreements or the Original Agreements become a “Discontinued Target”. 
 1.46.    “Disputes”
has the meaning set forth in Section 11.1(a). 
 1.47.    “DMF” means any drug master file filed
with the FDA, and any equivalent filing in other countries or regulatory jurisdictions. 

1.48.    “EMA” means the Regulatory Authority known as either the European Medicines Agency or the
European Agency for the Evaluation of Medicinal Products and any successor agency thereto. 
 1.49.    [***]. 

  
 5 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.50.    “Executive Officer” means, for Moderna, [***],
and for AstraZeneca, [***]. Either Party may change its Executive Officer upon written notice to the other Party; provided, that such replacement individual has decision-making authority on behalf of such Party in respect of this Agreement.

 1.51.    “Exploit” means to make, have made, import, use, sell, or offer for sale, including all
Development, Manufacturing and Commercialization activities, and “Exploiting” and “Exploitation” will have corresponding meanings. 

1.52.    “Facility” has the meaning set forth in Exhibit
A-1, Paragraph 3(b). 
 1.53.    “FDA” means the United
States Food and Drug Administration and any successor agency thereto. 
 1.54.    “FFDCA” means
the United States Food, Drug, and Cosmetic Act, as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and modifications thereto). 

1.55.     “FTE” means a full-time scientific or technical person, or in the case of less than a full-time
scientific or technical person, a full-time equivalent scientific or technical person year, carried out by an appropriately qualified employee or consultant of Moderna or its Affiliates, based on [***] person-hours [***] per year. 

1.56.    “FTE Costs” means the actual FTEs employed by Moderna or its Affiliates in the conduct of any
Services (excluding [***]) or other activities under any of the Transaction Agreements multiplied by the FTE Rate. The FTE Cost for each FTE will cover [***] with respect to such FTE. 

1.57.    “FTE Rate” means [***]dollars [***] per FTE, for the calendar year 2013, and adjusted annually
by [***] beginning with [***] and thereafter until the end of the Term. 
 1.58.    “Fully Burdened
Manufacturing Costs” means costs to perform Manufacturing Services and to supply a Moderna mRNA API and related inputs and services [***]; it being understood and agreed that: 

(i)    in the case of costs referred to [***] of this sentence [***]; provided, that [***]; and 

(ii)    in the case of costs referred to [***] of this sentence [***], which Manufacturing costs: (x) will include
[***], (y) will be calculated in accordance with [***] and (z) notwithstanding anything to the contrary, will exclude [***]. 

1.59.    “GAAP” means U.S. generally accepted accounting principles or International Financial Reporting
Standards, consistently applied, as designated and used by the applicable Party. 

  
 6 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.60.    “Good Laboratory Practice” or
“GLP” means the then current standards for laboratory activities for pharmaceuticals, as set forth in the FDA’s GLP regulations and/or ICH guidelines and applicable regulations. 

1.61.    “Government Official” has the meaning set forth in Section 11.4(a)(i). 

1.62.    “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the
rules and regulations promulgated thereunder. 
 1.63.    “Implementation Date” means April 29th, 2013
being the date on which the applicable waiting period under the Hart-Scott-Antitrust Improvement Act 1976 (as amended) expired or terminated following the HSR Filings (as defined in the Original Services and Collaboration Agreement) made in
connection with the execution of the Original Agreements. 
 1.64.    “Included Payments” has the
meaning set forth in the A&R Option Agreement. 
 1.65.    “Indemnification Claim Notice” has the
meaning set forth in Section 8.5(c). 
 1.66.    “Indemnified Party” has the meaning set forth in
Section 8.5(c). 
 1.67.    “Indirect Taxes” means VAT, sales taxes, consumption taxes and other
similar taxes required by law to be disclosed on the invoice. 
 1.68.    “Initial Payment” has the
meaning set forth in the A&R Option Agreement. 
 1.69.    “Issuing Party” has the meaning set
forth in Section 7.3(c). 
 1.70.    “Joint Patents” means all Collaboration Patents that are
jointly owned by the Parties in accordance with Section 2.5(a)(iii). 
 1.71.    “Joint Steering Committee;
JSC” has the meaning set forth in Section 3.2(a). 
 1.72.    “Joint Technology” means
all Collaboration Technology that is jointly owned by the Parties in accordance with Section 2.5(a)(iii). 

1.73.    “JPC” has the meaning set forth in Section 3.1. 

1.74.    “Knowledge” means the actual good faith understanding of [***]. 

1.75.    “Know-How” means all inventions, discoveries,
commercial, technical, scientific and other know-how and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences,
ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, assays and biological methodology, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical,
physical and analytical, laboratory, preclinical, clinical, safety, Manufacturing and quality control data and know-how, including regulatory data, study designs, protocols, laboratory notes and notebooks), in
all cases, whether or not confidential, proprietary, patented or patentable, in written, electronic or any other form now known or hereafter developed. 

  
 7 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.76.    “Law” or “Laws” means all
laws, statutes, rules, regulations, orders, judgments, or ordinances having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. 

1.77.    “LCIA” has the meaning set forth in Section 11.1(c). 

1.78.    “Losses” has the meaning set forth in Section 8.5(a). 

1.79.    “Manufacturing” means the production, manufacture, processing, filling, finishing, packaging,
labeling, shipping and holding of product or any intermediate thereof, including process development, process qualification and validation, scale-up, commercial manufacture and analytic development, product
characterization, stability testing, quality assurance and quality control. “Manufacturing” refers to both pre-clinical and clinical Manufacturing for Development, and Manufacturing for
Commercialization. 
 1.80.    [***] 

1.81.    “Manufacturing Know-How” has the meaning set forth in
Section 4.5(a). 
 1.82.    “Manufacturing Services” means the Moderna mRNA API Manufacturing
services performed by or on behalf of Moderna (a) in accordance with the Services Plan and the terms and conditions hereunder or (b) as part of the Development Pool Services. 

1.83.    [***] 

1.84.    [***] 

1.85.    “Master Clinical Supply Agreement” has the meaning set forth in Section 4.3(a). 

1.86.    “Master Commercial Supply Agreement” has the meaning set forth in Section 4.3(b). 

1.87.    “Master Supply Agreements” has the meaning set forth in Section 4.3(b). 

1.88.    “Material Anti-Corruption Law Violation” means a violation of an Anti-Corruption Law relating to
the subject matter of the Transaction Agreements which would if it were publicly known reasonably have a material adverse effect on either Party or on the reputation of a Party because of its relationship with the other Party. 

1.89.    “Materials” means any tangible chemical or biological material, including any compounds, DNA and
RNA (modified and unmodified), mRNA Constructs, Polypeptides, clones, cells, constructs, vectors, receptors and other nucleic acids, proteins, peptides and any expression product, progeny, derivative or other improvement thereto, along with any
tangible chemical or biological material embodying any Know-How. 

  
 8 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.90.    “Moderna” has the meaning set forth in
Recitals. 
 1.91.    “Moderna Collaboration In-License” has
the meaning set forth in Section 2.6(b). 
 1.92.    “Moderna Collaboration
Know-How” means any and all Collaboration Know-How owned by Moderna [***], including Moderna’s right and interest in any Joint Collaboration Know-How. 
 1.93.    “Moderna Collaboration Patents” means any and
all Patents that claim any of the Moderna Collaboration Know-How, including Moderna’s right and interest in any Joint Patents. 

1.94.    “Moderna Collaboration Technology” means the Moderna Collaboration Know-How and Moderna Collaboration Patents. For clarity, all Moderna Collaboration Technology will be “Controlled” for the purpose of this Agreement. 

1.95.    “Moderna Indemnitees” has the meaning set forth in Section 8.5(a). 

1.96.    “Moderna In-License” has the meaning set forth in
Section 2.6(a). 
 1.97.    “Moderna Know-How” means any
and all Know-How Controlled by Moderna or any of its Affiliates as of the Signing Date or as to which Moderna or any of its Affiliates obtains Control during the Term that [***]. 

1.98.    “Moderna mRNA API” means [***]. 

1.99.    “Moderna Other In-License” has the meaning set forth in
Section 2.6(e)(ii). 
 1.100.    “Moderna Patents” means those Patents that are Controlled by
Moderna or any of its Affiliates as of the Signing Date or as to which Moderna or any of its Affiliates obtains Control [***]. Schedule 1.100 sets forth those Moderna Patents in existence as of the Signing Date. 

1.101.    [***] 

1.102.    [***] 

1.103.    “Moderna Program Director” has the meaning set forth in Section 3.1. 

1.104.    “Moderna Representatives” has the meaning set forth in Section 11.4(a). 

1.105.    “Moderna Technology” means collectively, Moderna
Know-How and Moderna Patents. 
 1.106.    “mRNA Construct”
means [***]. 
 1.107.    “mRNA Technology” means any Know-How,
Materials and Patents directed or otherwise pertaining to [***], excluding any and all AstraZeneca [***] Technology [***] AstraZeneca [***] Technology. 

1.108.    [***] 

  
 9 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.109.    “Original Agreements” has the meaning set
forth in the Recitals. 
 1.110.    “Original Option Agreement” has the meaning set forth in the
Recitals. 
 1.111.     “Parties” has the meaning set forth in Recitals. 

1.112.    “Party” has the meaning set forth in Recitals. 

1.113.    “Patent” means (a) a patent or a patent application, (b) any additions, priority
applications, divisions, continuations, and continuations-in-part of any of the foregoing and (c) all patents issuing on any of the foregoing patent applications,
together with all invention certificates, substitutions, reissues, reexaminations, registrations, supplementary protection certificates, confirmations, renewals and extensions of any of (a), (b) or (c), and foreign counterparts of any of the
foregoing, but not including any rights that give rise to Regulatory Exclusivity Periods (other than supplementary protection certificates, which will be treated as “Patents“ hereunder). 

1.114.    “Patent Costs” means the reasonable, documented, out-of-pocket costs and expenses paid to outside legal counsel, and filing and maintenance expenses, actually and reasonably incurred by a Party in Prosecuting and Maintaining Patents and enforcing and
defending them. 
 1.115.    “Person” means any individual, partnership, joint venture, limited
liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. 

1.116.    “Polypeptide” means, [***]. 

1.117.    “Pre-clinical Activities” has the meaning set forth in
Exhibit A-1, Paragraph 2(a). 
 1.118.    “Product”
means a human, therapeutic product that includes as an active ingredient (whether alone or in combination with one or more other active ingredients) a Collaboration mRNA Construct [***] a Development Polypeptide. 

1.119.    “Product Warranty” has the meaning set forth in Exhibit
A-1, Paragraph 3(h). 
 1.120.    “Program Directors” has
the meaning set forth in Section 3.1. 
 1.121.    [***] 

1.122.     [***] 

1.123.    “Receiving Party” has the meaning set forth in Section 7.1(a). 

1.124.    “Regulatory Approval” means, with respect to a country or extra-national territory, any and all
approvals (including BLAs), licenses, registrations or authorizations of any Regulatory Authority necessary in order to commercially distribute, sell or market a product in such country or some or all of such extra-national territory, but not
including any pricing or reimbursement approvals. 

  
 10 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.125.    “Regulatory Authority” means any national
(e.g., the FDA), supra-national (e.g., the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, in any jurisdiction in the world, involved in the granting of Regulatory
Approval. 
 1.126.    “Regulatory Filings” means any submission to a Regulatory Authority of any
appropriate regulatory application together with any related correspondence and documentation, and will include any submission to a regulatory advisory board, marketing authorization application, and any supplement or amendment thereto. 

1.127.    “Release” has the meaning set forth in Section 7.3(c). 

1.128.    “Relevant Authority” means any court or government body, whether national, supra-national,
federal, state, local, foreign or provincial, including any political subdivision thereof, including any department, commission, board, bureau, agency, or other regulatory or administrative governmental authority or instrumentality, and further
including any quasi-governmental Person or entity exercising the functions of any of these. 

1.129.    “Reviewing Party” has the meaning set forth in Section 7.3(c). 

1.130.    [***] 

1.131.    [***] 

1.132.    “SEC” has the meaning set forth in Section 7.3(b). 

1.133.    [Reserved]. 

1.134.    “Services” means (a) the Development services to be performed by or on behalf of Moderna
pursuant to the Services Plan as set forth herein, (b) Development Pool Services, and (c) the Manufacturing Services. 

1.135.    “Services Period” means for each Research Target and each Research Polypeptide [***] such
Research Target, the period commencing on nomination of such Research Target or ([***]) and in both cases ending [***] after the Amendment Effective Date or, if earlier the date on which such Research Target becomes a Discontinued Target. 

1.136.    “Services Plan” has the meaning set forth in Section 2.3(a). 

1.137.    “Services Program” means the program of services for Development of mRNA Constructs using
Moderna Technology in the applicable AstraZeneca Fields that is engaged in by or on behalf of the Parties prior to the Amendment Effective Date, under the Original Services and Collaboration Agreement and with effect on and from the Amendment
Effective Date, under this Agreement, including Moderna’s performance of the Services and the Parties’ performance of activities under the Services Plan. 

1.138.    “Services Program Term” has the meaning set forth in Section 2.4(a). 

  
 11 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 1.139.    “Signing Date” means March 20, 2013. 

1.140.    “Sublicensee” means (a) in the case of AstraZeneca, any Person (other than an Affiliate or
a Distributor of AstraZeneca) that is granted a sublicense as permitted by Section 3.6(a) of the A&R Option Agreement (or an option to take such a sublicense), either (i) directly by AstraZeneca or (ii) indirectly by any Person
granted rights by AstraZeneca pursuant to subclause (a)(i); or (b) in the case of Moderna, any Person (other than an Affiliate or Distributor of Moderna) that is granted a sublicense as permitted by Section 3.6(a) of the A&R Option
Agreement (or an option to take such a sublicense), either (i) directly by Moderna or (ii) indirectly by any Person granted rights by Moderna pursuant to subclause (b)(i). 

1.141.    “Supply Failure” means [***]. 

1.142.    “Target” means [***]. 

1.143.     “Tax” and “Taxation” means any form of tax or taxation, levy, duty, charge,
social security charge, contribution, or withholding of whatever nature (including any related fine, penalty, addition to tax, surcharge or interest) imposed by, or payable to, a Tax Authority. Notwithstanding anything herein to the contrary, Taxes
will not include any Indirect Taxes. 
 1.144.    “Tax Authority” or “Tax Authorities”
means any government, state or municipality, or any local, state, federal or other fiscal, revenue, customs, or excise authority, body or official anywhere in the world, authorized to levy tax. 

1.145.    “Term” has the meaning set forth in Section 9.1. 

1.146.     “Third Party” means any Person other than
Moderna, AstraZeneca and their respective Affiliates. 
 1.147.    “Third Party Claims” has the meaning
set forth in Section 8.5(a). 
 1.148.    “Transaction Agreements” means collectively,
(a) this Agreement, (b) the A&R Option Agreement and (c) that certain Put Agreement between the Parties dated November 25, 2014. 

1.149.    “Transferred API(s)” has the meaning set forth in Section 4.5. 

1.150.    “Triggering Event” has the meaning set forth in Section 4.7. 

1.151.    “United States” or “U.S.” means the United States of America, including its
territories and possessions, the District of Columbia and Puerto Rico. 
 1.152.    “Upfront Payment”
has the meaning set forth in Section 6.1. 

  
 12 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 2.     Services Program.  

2.1.    General. During the Services Program Term, Moderna will perform the Services and the Parties will otherwise
conduct the Services Program on the terms and conditions set forth in this Agreement to identify and validate Research Polypeptides and optimize Collaboration mRNA Constructs [***] such Research Polypeptides. For each Research Polypeptide, the
objective of the Services Program is to [***] that [***] such Research Polypeptide and meets the [***] Criteria. 

2.2.    Research Targets and Research Polypeptides. 

(a)    Nomination. From the Amendment Effective Date until the [***] anniversary of the Amendment Effective Date
(the “Nomination Period”), AstraZeneca may nominate up to [***] Research Polypeptides for each AstraZeneca CV Target and the AstraZeneca Oncology Target by providing written notice to Moderna of same, provided that, subject to the
overall cap of [***] Research Polypeptides per Research Target AstraZeneca may [***]. The Program Directors will maintain a current list of Research Targets and Research Polypeptides that will be Developed as a part of the Services Plan. For each
Research Target, the list of Research Polypeptides nominated as of the Amendment Effective Date is set forth in Appendix A. For clarity, each such nominated Research Polypeptide counts towards the maximum nomination of [***] Research
Polypeptides per Research Target, including following such Research Polypeptide becoming a Development Polypeptide or Discontinued Polypeptide. Subject to such maximum, AstraZeneca may make additional nominations of Research Polypeptides by
providing an updated version of Appendix A to Moderna as provided in Section 11.16, [***]. For the purposes of this Section 2.2(a), with respect to each Research Target, each Polypeptide nominated by AstraZeneca that has [***] will be
counted towards the overall cap of [***] Research Polypeptides for such Research Target even if such Polypeptides are [***]. 

(b)    Development of [***]. AstraZeneca may Develop Products that [***] as set forth in Section 4.4 of the
A&R Option Agreement. In particular, as part of the Services Program, AstraZeneca may Develop [***] Product Candidates that [***]. 

(c)    Exclusion of Research Targets and Research Polypeptides from the Services Program. 

(i)     AstraZeneca may, at any time, elect to exclude any Research Target from the Services Program by providing an
updated version of Appendix A to Moderna as provided in Section 11.16, [***]. Upon Moderna’s receipt of such written notice, such Research Target will be excluded from the Services Program and will automatically become a Discontinued
Target. For clarity, termination of Development activities relating to a particular [***] Product Candidate for a [***] Target shall not result in [***]. 

(ii)    For each Research Target in the Services Program, AstraZeneca will keep Moderna informed of progress towards
satisfaction of the Continuation Criteria for such Research Target at each JSC meeting, including by providing the JSC at each meeting of the JSC a report (written or oral) summarizing AstraZeneca’s Development activities with respect to such
Research Target, including a summary of any material data and results generated by any of such Development activities. In addition, for each Research Target in the Services Program, AstraZeneca will notify Moderna in writing when in
AstraZeneca’s reasonable determination a Research Target has met the applicable Continuation Criteria. AstraZeneca will include in any such written notice such information and data as is necessary for Moderna to verify that the

  
 13 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
applicable Research Target has met the applicable Continuation Criteria. To continue in the Services Program, each Research Target (other than [***]) must meet the [***] for such Research Target
on or before the [***] and the [***] for such Research Target on or before the [***]. If with respect to any Research Target, AstraZeneca has not met the applicable Continuation Criteria, or has not provided notice that the applicable Continuation
Criteria have been met, in each case on or prior to such [***], the Research Target will be excluded from the Services Program and automatically become a Discontinued Target. In the event that Moderna disagrees with AstraZeneca’s determination
as to whether a Research Target has met the [***] or [***] for such Research Target (a “Continuation Criteria Dispute”), Moderna shall provide AstraZeneca with written notice thereof within [***] days after Moderna’s receipt of
the applicable notice from AstraZeneca asserting that the applicable Continuation Criteria have been met (the “Continuation Criteria Dispute Notice”) and Section 11.1(b) (but not Section 11.1(c)) shall apply. Development
activities with respect to a Research Target will continue notwithstanding a Continuation Criteria Dispute. If during the period in which the Parties are seeking to resolve a Continuation Criteria Dispute, [***]; provided, that [***]. In the
event that Moderna does not provide AstraZeneca with the Continuation Criteria Dispute Notice within the [***] day period specified in this Section 2.2(c)(ii), Moderna shall be deemed to have agreed with AstraZeneca’s determination as set
forth in the applicable notice from AstraZeneca asserting that that the applicable Continuation Criteria have been met. 

(iii)    If a Research Target becomes a Discontinued Target, in addition to any other consequences applicable to
Discontinued Targets set forth in the Transaction Agreements, Sections 2.2 and 3.4 of the A&R Option Agreement will apply. 

2.3.    Services Plan. 

(a)    Performance. During the Services Period for each Research Target (and all Research Polypeptides for such
Research Target), Moderna will perform the Services and the Parties will otherwise carry out the Services Program for such Research Target in accordance with a written research plan (the “Services Plan”). The Services Plan will set
forth, on a Research Target-by-Research Target basis, all Development activities of the Parties with respect to Collaboration mRNA Constructs generated by Moderna and
[***] Research Polypeptides for such Research Target during the applicable Services Period. The purpose of the Services Plan is to detail the responsibilities and activities of (1) Moderna with respect to carrying out the Services, and
(2) the Parties with respect to otherwise carrying out the Services Program. The Services Plan will include [***]. The Parties agree that as part of any Services Plan, AstraZeneca may request reasonable quantities and Moderna will use
Commercially Reasonable Efforts to provide reasonable quantities of [***] to AstraZeneca at a cost to AstraZeneca of [***] for use as part of the Services Program for a Research Target. For clarity, a failure by Moderna to supply such [***] will not
result in a Triggering Event. The Services Plan will provide that Moderna (and not AstraZeneca) is responsible for Manufacturing mRNA Constructs. The Services Plan may be updated and amended by the JSC in accordance with Section 3.2(c) from
time to time.
 (b)    Obligations Under the Services Plan. Moderna will use Commercially Reasonable Efforts to
perform (itself or through its Affiliates or by permitted subcontracting pursuant to Section 2.10) the Services, and each Party will otherwise use Commercially Reasonable Efforts to perform (itself or through its Affiliates or by permitted
subcontracting pursuant to Section 2.10) 

  
 14 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
its respective obligations under the Services Plan. Each Party will cooperate with and provide reasonable support to the other Party in such other Party’s performance of its responsibilities
under the Services Plan. Each Party will keep the other Party reasonably informed of such Party’s Development activities under the Services Program and will reasonably consult with such other Party and reasonably consider such other
Party’s comments and advice with respect to all material decisions relating to such activities. The Parties acknowledge and agree, however, that no outcome or success is or can be assured and that failure to achieve desired results will not in
and of itself constitute a breach or default of any obligation in this Agreement (notwithstanding the focus of the Services Program described above). The Parties will Develop and Commercialize under the Transaction Agreements only Collaboration mRNA
Constructs, and no other mRNA Constructs. 
 (c)    FTEs.    The Services Plan will set forth
the expected number of FTEs required to perform the Services allocated to Moderna (excluding, for clarity, Manufacturing Services). AstraZeneca will reimburse Moderna [***] for Moderna’s FTE Costs for such FTEs. [***]. Those individuals
selected by Moderna to perform the Services and otherwise support the Development and other activities to be undertaken by Moderna under the Services Plan and as part of the Services Program will [***]. In the event that AstraZeneca has concerns
regarding the selection of an individual to perform the Services or other activities under this Agreement, the Parties will discuss such concerns in good faith. 

(d)    [***]. Moderna will (a) use good faith efforts to ensure [***]; and (b) use diligent efforts to
ensure [***]. For clarity, any mRNA Constructs that are not Developed in the course of performing activities under the Services Program (under or in connection with this Agreement or the Original Services and Collaboration Agreement) will not
constitute Collaboration mRNA Constructs. 
 (e)    Updates. Any modifications or amendments to the Services Plan
that are proposed by either Party will be subject to review and prior approval by the JSC pursuant to and in accordance with the terms of Section 3.2(c). 

2.4.    Services Program Term; Development Pool Services. 

(a)    Duration. Unless (i) terminated pursuant to the terms hereof, or (ii) extended by mutual agreement
of the Parties, the term of the Services Program with commence on the Implementation Date and will continue until expiration of the period of [***] from the Amendment Effective Date (the “Services Program Term”); provided that
if the Services Period is extended for any Research Target pursuant to Section 2.2(c)(ii), the Services Program Term as applicable to such Research Target shall continue until expiration of such Service Period. 

(b)    Development Pool Services. During the period after the end of the applicable Services Period until the [***]
of the Implementation Date, if AstraZeneca reasonably requests that Moderna perform additional Services during the Option Agreement Term (excluding, for clarity, Manufacturing Services) in support of the evaluation of any Development Pool Candidate
(“Development Pool Services”), the Parties will negotiate in good faith the terms and conditions of such performance. In the event the Parties agree on such terms and conditions, Moderna will use Commercially Reasonable Efforts to
perform (itself or through its Affiliates or by permitted subcontracting pursuant to Section 2.10) such Development Pools Services in accordance with 

  
 15 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
such terms and conditions as may be agreed to by the Parties, and AstraZeneca will reimburse Moderna [***] for Moderna’s FTE Costs incurred in performing such Development Pool Services.
[***]. 
 (c)    Termination of Services. All Services and other Development work hereunder will terminate on the
[***] of the Implementation Date. 
 2.5.    Ownership of Technology. 

(a)    Ownership of Technology  

(i)    Ownership of [***]. Subject to the license grants to AstraZeneca under any Transaction Agreement, as between
the Parties, Moderna will own and retain all right, title and interest in and to all [***]. Accordingly, AstraZeneca will promptly disclose to Moderna in writing, the conception or reduction to practice, or the discovery, development or making of
any [***]. AstraZeneca, for itself and on behalf of its Affiliates, hereby assigns (and to the extent such assignment can only be made in the future hereby agrees to assign), to Moderna all its right, title and interest in and to any [***].
AstraZeneca will cooperate, and will cause the foregoing persons and entities to cooperate, with Moderna to effectuate and perfect the foregoing ownership, including by promptly executing and recording assignments and other documents consistent with
such ownership. Notwithstanding the foregoing, [***] will not include any [***] (collectively, “AstraZeneca [***] Technology”). 

(ii)    Ownership of other arising Technology. Subject to Section 2.5(a)(i), all Know-How, Materials and Patents conceived, discovered, developed or otherwise made, by or on behalf of either Party (or its Affiliates or Sublicensees) either alone or jointly with Third Party(ies) or by the Parties
or their Affiliates jointly under or in connection with the Transaction Agreements, whether or not conceived, discovered, developed or otherwise made at a facility owned or controlled by such Party and whether or not patented or patentable, and any
and all Patent and other intellectual property rights with respect thereto will be owned in accordance with inventorship and in accordance with applicable law in the United States. 

(iii)    United States Law. The determination of whether Know-How,
Materials and Patents are conceived, discovered, developed or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights) therein, will, for purposes of this
Agreement, be made in accordance with applicable law in the United States. In the event that United States law does not apply to the conception, discovery, development or making of any Know-How, Materials or
Patents hereunder, each Party will, and does hereby, assign, and will cause its Affiliates and sublicensees to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Know-How, Materials and Patents as well as any intellectual property rights with respect thereto, as is necessary to fully effect ownership as would have been determined under U.S. law. 

(iv)    [***]. 

(b)    Exploitation of Joint Technology. Subject to Section 2.5(a)(i), 2.5(a)(iii) and to the license
grants under the Transaction Agreements, the Parties will each own an equal, undivided interest in any and all Joint Technology. Each Party will exercise its ownership rights in and to 

  
 16 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
such Joint Technology, including the right to license and sublicense or otherwise to Exploit, transfer or encumber its ownership interest, without an accounting or obligation to, or consent
required from, the other Party, but subject to the license grants under the Transaction Agreements. At the reasonable written request of a Party, the other Party will in writing grant such consents and confirm that no such accounting is required to
effect the foregoing regarding Joint Technology. Each Party will promptly disclose to the other Party in writing, and will cause its Affiliates, licensees and permitted sublicensees to so disclose, the development, making, conception or reduction of
practice of any inventions in connection with work conducted under or in connection with this Agreement or the Original Services & Collaboration Agreement. Each Party will, and does hereby, assign, and will cause its Affiliates, licensees
and sublicensees to so assign, to the other Party, without additional compensation, such right, title and interest in and to any Joint Technology as well as any intellectual property rights with respect thereto, as is necessary to fully effect the
joint ownership provided for in the first sentence of this Section 2.5(b). 
 (c)    No Implied Rights. No
license, sublicense or other right is or will be created or granted hereunder by implication, estoppel or otherwise. Any licenses, sublicenses or rights will be granted only as expressly provided in the Transaction Agreements. Neither Party nor any
of its Affiliates will use or practice any Know-How, Materials or Patents licensed or provided to such Party or any of its Affiliates outside the scope of or otherwise not in compliance with the rights and
licenses granted to such Party and its Affiliates under the Transaction Agreements. 
 2.6.    Third Party In-Licenses. 
 (a)    Moderna
In-Licenses. In the event that Moderna identifies any Patents or Know-How of a Third Party that may [***], Moderna may independently negotiate and enter into an
agreement to obtain a license or other rights to such Patents or Know-How (each such agreement, a “Moderna In-License”); provided, that Moderna
(i) will [***] and (ii) will reserve the right in such Moderna In-License to [***]. 

(b)    Moderna Collaboration In-Licenses. If during the Services Program
Term Moderna enters into any Moderna In-License, Moderna will, through written notice, bring such Moderna In-License to the attention of the JSC [***]. If a Moderna In-License is brought to the attention of the JSC pursuant to this Section 2.6(b), the Parties will, through the JSC, discuss in good faith whether such Moderna
In-License should be made available for use [***]. Moderna will disclose the terms of the Moderna In-License to the JSC, subject to [***], and otherwise provide
AstraZeneca with such assistance and information that AstraZeneca reasonably requires to assess whether or not [***]. If AstraZeneca notifies Moderna in writing within [***] days after the time when Moderna brought the Moderna In-License to the attention of the JSC or AstraZeneca, as applicable, that such Moderna In-License should be made available for use by [***] (each such Moderna In-License, a “Moderna Collaboration In-License”), then (i) the Patents and Know-How in-licensed under such Moderna In-License will be deemed Moderna Technology, and (ii) AstraZeneca will be required to make the payments set forth in Section 2.8(b);
provided, that [***]. If AstraZeneca concludes that such Moderna In-License should not be made available [***], then subject to Section 2.6(c), [***]. 

  
 17 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 (c)    Conversion of Moderna
In-Licenses. AstraZeneca may elect to convert any Moderna In-License to a Moderna Collaboration In-License by
(i) providing written notice to Moderna of the same and (ii) [***]; provided, [***]. Upon Moderna’s receipt of such notice [***], such Moderna In-License will be a Moderna Collaboration In-License hereunder, and the provisions of this Agreement applicable to Moderna Collaboration In-Licenses will apply with respect to such Moderna In-License. Notwithstanding the foregoing, prior to converting any Moderna In-License to a Moderna Collaboration In-License, the
Parties will agree on [***]. 
 (d)    Moderna Collaboration In-License
Requirements. AstraZeneca will abide, and will cause all its Affiliates and applicable Sublicensees to abide, by all requirements of each Moderna Collaboration In-License in all material respects (and in
any case in all respects in the case that [***]), to the extent applicable to sublicensees thereunder and to the extent disclosed by Moderna to AstraZeneca pursuant to Section 2.6(b) prior to AstraZeneca’s conclusion to have the Moderna In-License made available, with the understanding that disclosure by Moderna of any Moderna Collaboration In-License to AstraZeneca will be deemed disclosure of such
requirements of such Moderna Collaboration In-License so disclosed to AstraZeneca. 

(e)    AstraZeneca In-Licenses; Moderna Other
In-Licenses. 
 (i)    In the event that AstraZeneca identifies any Patents
or Know-How of a Third Party that [***] (each such agreement, an “AstraZeneca In-License”). AstraZeneca will notify Moderna of such AstraZeneca In-License. In the event that such notice is given and Moderna concludes that such AstraZeneca In-License should be made available [***], then the Parties will discuss in good
faith whether and on what terms AstraZeneca would grant Moderna rights under any such AstraZeneca In-License. 

(ii)    Subject to Section 2.6(a), in the event that Moderna identifies any Patents or
Know-How of a Third Party that [***], Moderna may independently negotiate and enter into an agreement to obtain a license or other rights to such Patents or Know-How
[***] (each such agreement, a “Moderna Other In-License”). Moderna may notify AstraZeneca of such Moderna Other In-License. In the event that such
notice is given and [***] such Moderna Other In-License should be made available [***], then the Parties will discuss in good faith whether and on what terms Moderna would grant AstraZeneca rights under any
such Moderna Other In-License. 
 (f)    [***] 

2.7.    [***] 

2.8.    Services Program Expenses. 

(a)    Expenses. Except as otherwise provided in this Agreement, each of Moderna and AstraZeneca will be responsible
for all of its internal and out-of-pocket costs and expenses in connection with the performance of the Services Plan; provided, that AstraZeneca will reimburse
Moderna for any direct, reasonable and verifiable out-of-pocket costs that are specified in and in accordance with any budget for the Services Plan and incurred by
Moderna in connection with the performance of the Services or other activities as a part of the Services Program. Moderna will issue an invoice each month covering costs that are reimbursable by AstraZeneca pursuant to the foregoing sentence.
AstraZeneca agrees to pay each such invoice within [***] days of AstraZeneca’s receipt thereof, subject to the provisions in Section 6.2. 

  
 18 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 (b)    Moderna Collaboration
In-License Payments. 
 (i)    If any payments previously disclosed to
AstraZeneca pursuant to Section 2.6(b) become due during the Services Program Term under any Moderna Collaboration In-License, [***]; provided, that (i) [***] within [***] days of [***] (excluding
[***] and (ii) such payment obligation is not specifically attributable to activities under the A&R Option Agreement, which will be addressed thereunder. 

(ii)    Notwithstanding Section 2.8(b)(i), if any payments previously disclosed to AstraZeneca pursuant to
Section 2.6(b) become due during the Services Program Term under any Moderna Collaboration In-License that is a [***]; provided, that (1) [***] within [***] (excluding [***]. 

2.9.    Services Program Records, Reports and Materials. 

(a)    Records. Each Party will maintain, or cause to be maintained, records of its activities under the
Services Program in sufficient detail and in good scientific manner appropriate for scientific, Patent and regulatory purposes, that will properly reflect all work included in the Services Program, for a period of at least [***] after the creation
of such records, but in no event less than required by applicable Laws. Each Party will have the right to request a copy of any such records. 

(b)    Services Program Reports. Each Party will furnish to the JSC a summary written report within [***] days
after each [***] and [***] occurring during the Services Program Term, describing its progress under the Services Plan as part of the Services Program during the previous [***] period. The JSC may periodically request summary reports from either
Party updating the JSC as to the progress under the Services Plan during any intermediate intervening periods between such [***] reports. 

(c)    Materials. 

(i)    Other than as set forth in Section 4, each Party will, during the Services Program Term, as a matter of course
as described in the Services Plan or upon the other Party’s reasonable written request, furnish to each other samples of Materials that are in such Party’s Control and [***]. 

(ii)    Each Party will use any Materials provided by the other Party hereunder, including as set forth in Section 4
and Exhibit A-1, only in accordance with the Services Plan and otherwise in accordance with the terms and conditions of this Agreement and any reasonable instructions provided by the Party furnishing
the Materials. Except with the prior written consent of the supplying Party (such consent not to be unreasonably withheld, delayed or conditioned), the Party receiving any Materials will not [***]. All Materials delivered to the receiving Party,
other than pursuant to [***], will remain the sole property of the supplying Party and will be used in compliance with all applicable Law. The Materials supplied under this Agreement will be used with prudence and appropriate caution in any
experimental work because not all of their characteristics may be known. This Section 2.9(c)(ii) will not apply to [***].  

  
 19 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 2.10.    Permitted Subcontracting and Sublicensing. Subject to the
other terms of the Transaction Agreements, including Section 4 with respect to Manufacturing Services, Section 4.6 of the A&R Option Agreement with respect to the Development Pool Services, any Master Supply Agreement (and any
associated Quality Assurance Agreement), and Section 2.12, Moderna may subcontract the Services and each Party may otherwise subcontract any of its activities to be performed under the Services Plan to an Affiliate or a Third Party;
provided, that no such permitted subcontracting shall relieve the subcontracting Party of any of its obligations (except to the extent satisfactorily performed by such subcontractor). In the event that either Party subcontracts
activities pursuant to this Section 2.10 to an Affiliate or Third Party, such Affiliate or Third Party will have entered into a written agreement with such Party that includes terms and conditions protecting and limiting use and disclosure of
Confidential Information and Materials and Know-How at least to the same extent as under this Agreement, and requiring such Third Party and its personnel to assign to such Party all right, title and interest
in and to any Patents, Know-How and Materials created, conceived or developed in connection with the performance of subcontracted activities to the extent required to Exploit Product Candidates. Any such
subcontracting activities will be described in the reports for the Services Program required by Section 2.9(b). To the extent that any subcontractor needs a sublicense to perform the
Services, Section 3.6 of the A&R Option Agreement will apply. 
 2.11.    Regulatory Activities. From
the Implementation Date until the [***] of the Implementation Date, and subject to any Third Party confidentiality obligations, each Party will through the JSC keep the other Party appropriately informed of [***]. Upon the request of either Party,
and subject to any Third Party confidentiality obligations, the Parties will discuss in good faith appropriate [***]. Each Party will use Commercially Reasonable Efforts to [***]. Notwithstanding the foregoing, (a) except to the extent required
by applicable Law, AstraZeneca will have the sole right to [***]; and (b) this Section 2.11 (i) will not require Moderna to disclose any [***] and (ii) will terminate after the Program Services Term upon [***]. 

2.12.    Applicable Laws and Bioethics Policy. The Services and Services Program (and any applicable Development
Pool Services) to be conducted by each Party (including by its subcontractors) pursuant to this Agreement or the A&R Option Agreement will be carried out in good scientific manner and in compliance with all applicable Laws, as well as the
AstraZeneca bioethics policy attached at Schedule 2.12, to attempt to achieve efficiently and expeditiously the objectives of the applicable Services Program (or Development Pool Services, if applicable). Notwithstanding
the provisions of Section 2.10, in respect of any Services (or Development Pool Services, if applicable) to be performed by or on behalf of Moderna to be initiated after the Implementation Date, Moderna and AstraZeneca will mutually agree
[***]. 
 3.    Governance. 

3.1.    Services Program Management. Following the Implementation Date, each Party will appoint a person who will
oversee day-to-day contact between the Parties for all matters related to the collaboration and management of the Services Program activities in between meetings of the
JSC and the joint patent committee as constituted under the A&R Option Agreement (such joint patent committee, the “JPC”) and will have such other responsibilities as the Parties may agree in writing after the
Implementation Date. One person will be designated by AstraZeneca (the “AstraZeneca Program Director”) and one person will be designated by Moderna 

  
 20 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
(the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the
other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. 

3.2.    Joint Steering Committee. 

(a)    Formation and Membership. Following the Implementation Date, the Parties will establish a joint steering
committee (the “Joint Steering Committee” or “JSC”), comprised of [***] representatives of Moderna and [***] representatives of AstraZeneca. Each JSC member will be a senior development leader or have similar
experience and expertise as a senior development leader. Each Party may replace its representatives on the JSC at any time upon written notice to the other Party. With the consent of the other Party (such consent not to be unreasonably withheld,
delayed or conditioned), each Party may invite non-voting employees and consultants to attend meetings of the JSC, subject to their agreement to be bound to the same extent as a permitted subcontractor under
Section 2.10. Program Directors will attend JSC meetings as participating non-members. 

(b)    Meetings. While in existence, the JSC will meet each [***] (or more frequently as may be determined by the
JSC) and may hold meetings in person or by audio or video conference as determined by the JSC, but at a minimum, [***] of such meetings each calendar year starting in 2013 will be in person (which in-person
meeting will be held at [***]). Meetings of the JSC will be effective only if at least [***] representative of each Party is present or participating. Each Party will be responsible for all of its own expenses of participating in the meetings. The
Parties will endeavor to schedule meetings of the JSC at least [***] in advance. The JSC will determine the JSC operating procedures and will codify these operating procedures in the written minutes of the first meeting (or subsequent meetings as
such procedures are updated). The JSC will prepare and circulate a meeting agenda prior to each such meeting. The Parties will alternate in preparing written minutes of such meeting, and the preparing Party will circulate such minutes
within [***] days after such meeting. The Parties will agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JSC. Each Party will designate one of its three representatives who is empowered by such Party
to make decisions related to the performance of such Party’s obligations under the Transaction Agreements to act as the co-chair of each JSC. The co-chairs will be
responsible for overseeing the activities of its JSC members consistent with the responsibilities set forth in Section 3.2(c). 

(c)    Responsibilities. The JSC will oversee the Services Program and the performance of the Services Plan. It is
envisioned that the JSC will form project teams to deal with the day-to-day work to execute the Services Plan for particular Research Polypeptides. Without limiting the
generality of the foregoing, within such scope, the JSC will have the following responsibilities: 
 (i)    Review
Moderna’s performance of the Services and the Parties’ other efforts and progress under the Services Plan; 

(ii)    Review and approve of the Services Program; 

  
 21 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 (iii)    Propose and approve of any proposed modifications or amendments
to a Services Plan and the Services Program (other than minor, day-to-day modifications to the Services Plan and the Services Program made by the project teams (if
applicable) and changes that do not affect Moderna), including the selection of Collaboration mRNA Constructs for additional work as part of the Services Program; 

(iv)    Prioritize and oversee execution of specific activities to be performed under the Services Plan and the Services
Program; 
 (v)    Resolve all disputes referred to the JSC by any subcommittee or project teams established by the JSC;

 (vi)    Review and approve the [***]; 

(vii)    Review and approve quarterly reports from Moderna setting forth [***] incurred by Moderna for which Moderna seeks
reimbursement; 
 (viii)    Determine the specific number of FTEs [***] to be dedicated by Moderna in performing the
Services and Development activities under the Services Plan and as part of the Services Program in accordance with Section 2.3(c); 

(ix)    Review data, reports or other information submitted by either Party with respect to development activities
performed under a Services Plan and the Services Program by or on behalf of such Party; 
 (x)    Update the Services
Plan to include activities with respect to new Research Polypeptides; 
 (xi)    Monitor that all activities are
compliant with AstraZeneca’s Bioethics policy and other compliance standards of importance to AstraZeneca or Moderna; 

(xii)    Form such other committees or project teams as the JSC may deem appropriate (including any project teams to deal
with the day-to-day work to execute the Services Plan for a particular Research Polypeptide) and oversee the work of the JPC and any other committees or project teams
formed by the JSC (but without alteration of the governance of the JPC as set forth in Section 10.1 of the A&R Option Agreement), including by receiving and reviewing reports and other information submitted by those joint committees and
project teams (if applicable); provided, that any such committee or project team may make recommendations to the JSC but may not be delegated JSC decision-making authority; 

(xiii)    Review and approve the regulatory pathway for the approval by Regulatory Authorities of Collaboration mRNA
Constructs as medicinal products and material submissions to Regulatory Authorities with respect to such pathway; 

(xiv)    Review proposed publications regarding the results of the Services Program proposed to be published in accordance
with Section 7.2. 

  
 22 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 (xv)    Address such other matters relating to the activities of the
Parties under this Agreement as either Party may bring before the JSC, including any matters that are expressly for the JSC to decide as provided in this Agreement; and 

(xvi)    Attempt to resolve any disputes relating to the Transaction Agreements on an informal basis. 

(d)    Decision-making. The [***] JSC representatives of each Party will collectively have one (1) vote. The
JSC members will use reasonable efforts to reach agreement on all matters. If, despite such efforts, agreement on a particular matter cannot be reached by the JSC within [***] days after the JSC first considers such matter (or such shorter time as
may be reasonable in the circumstances), then [***]. 
 (e)    Resolution of Certain Matters. Notwithstanding the
provisions of Section 3.2(d) in the event of a dispute or disagreement arising in, or referred to, the JSC relating to [***] that cannot be resolved by the members of the JSC, upon the written request of a Party, such matter will be referred to
the Executive Officers (or their designees, which designee is required to have decision-making authority on behalf of such Party), who will attempt in good faith to resolve such dispute by negotiation and consultation for a [***] period following
receipt of such written notice. If, despite such efforts, agreement on a particular matter cannot be reached by the Executive Officers within such [***] period, then [***]. 

(f)    Limits on JSC Authority. Each Party will retain the rights, powers and discretion granted to it under this
Agreement and no such rights, powers, or discretion will be delegated to or vested in the JSC unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. The JSC will not have
the power to [***]. Any dispute between the Parties regarding the issues set forth in this Section 3.2(f) will be resolved pursuant to the procedures set forth in Section 11.1. 

(g)    Scope of JSC Responsibilities and Term. Unless otherwise agreed by the Parties or as provided in
Section 9.4, the JSC will continue to exist throughout the Term; provided that [***] after the end of the Services Program Term, the responsibilities of the JSC will be limited to those allocated to it in Section 4, Exhibit A-1 and as provided in Section 5.4 of the A&R Option Agreement. After expiration of the Services Program Term, the membership of the JSC will be adjusted to reflect such amended responsibilities, and will
meet as reasonably required, and on such notice, as necessary to fulfil those responsibilities, each as determined by the JSC; provided that if a meeting of the JSC is required to address any matter for which the JSC is responsible, either Party may
call such meeting on not less than [***] days’ notice). 
 4.    Manufacturing. 

4.1.    General Obligation to Supply. Subject to the terms and conditions of the Transaction Agreements and
in particular this Section 4, Exhibit A-1 and Exhibit A-2, Moderna will Manufacture and supply to AstraZeneca, and AstraZeneca will purchase
exclusively from Moderna, such quantities of Moderna mRNA API as AstraZeneca may reasonably require in connection with the Exploitation of Collaboration mRNA Constructs, Product Candidates and Products; provided, that such obligation to
purchase exclusively from Moderna will no longer 

  
 23 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
apply with respect to Moderna mRNA API for a given Product at such time as [***]. Notwithstanding the foregoing, the Parties acknowledge and agree that AstraZeneca will have no right to acquire
from Moderna, and Moderna will have no obligation to Manufacture and supply to AstraZeneca, any Moderna mRNA API for use in connection with the Commercialization of any Product unless and until AstraZeneca has exercised its Option as set forth in
Section 6.6 of the A&R Option Agreement and paid the applicable Initial Payment under the A&R Option Agreement with respect to such Product. Except (a) following a Triggering Event as described in Section 4.7,
(b) on a Product-by-Product basis, at such time as [***], or (c) [***], neither AstraZeneca nor any Affiliate of AstraZeneca (nor any others on behalf of or under
license or sublicense from AstraZeneca or any of its Affiliates) will Manufacture (i) any Moderna mRNA API or (ii) Product, except for the Manufacture of Product using Moderna mRNA API supplied by or on behalf of Moderna. For clarity, the
rights and obligations under this Section 4, Exhibit A-1 and Exhibit A-2 relate solely to unformulated Moderna mRNA API, unless otherwise agreed by
the Parties. AstraZeneca, for itself, its Affiliates and all others acting on behalf of or under license or sublicense from AstraZeneca or any of its Affiliates, will purchase from Moderna all mRNA Constructs to be Exploited under any of the
Transaction Agreements or any of the Master Supply Agreements, unless and until (i) there is a Triggering Event, or (ii) [***]. 

4.2.    Non-cGMP Supply for Services Program. In accordance with Exhibit
A-1, Moderna will Manufacture and supply AstraZeneca with non-cGMP Moderna mRNA API for use in support of the Services Program, Development Pool Services or Pre-Clinical Activities, as applicable, with respect to each applicable Collaboration mRNA Construct. For clarity, the charges for such Manufacturing Services are as provided in Exhibit A-1 and are inclusive of [***]. 
 4.3.    cGMP Supply Agreements.  

(a)    AstraZeneca and Moderna have entered into a master clinical supply agreement (dated April 23, 2015) and related
quality agreement pursuant to which Moderna will continue to supply to AstraZeneca cGMP Moderna mRNA API for clinical Development of Product Candidates and Products and for any other activities under the Transaction Documents that require cGMP
Moderna mRNA API, all in accordance with the Transaction Agreements (as may be amended, the “Master Clinical Supply Agreement”) as required under Section 4.1, in such quantities as AstraZeneca may order in accordance with the
terms and conditions of such agreement. 
 (b)    At any time after [***], AstraZeneca may notify Moderna that it
desires to commence negotiations of a master commercial supply agreement and related quality agreement pursuant to which Moderna will supply to AstraZeneca cGMP Moderna mRNA API as required under Section 4.1, in such quantities as AstraZeneca
may order in accordance with the terms and conditions of such agreement for Commercialization of Products in accordance with the Transaction Agreements. Not later than [***] after such notice, AstraZeneca and Moderna will enter into such agreement
(the “Master Commercial Supply Agreement” and, together with the Master Clinical Supply Agreement, the “Master Supply Agreements”). 

(c)    Each Master Supply Agreement will contain such terms as are reasonable and customary for similar supply agreements,
including the terms and conditions described in Exhibit A-2, and will be negotiated and agreed by the Parties in good faith. In the event that the Parties

  
 24 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
are not able to agree on such terms to be included in either Master Commercial Supply Agreement within the applicable time periods specified in clauses (a) or (b), as applicable, after
negotiation and escalation under Section 11.1(b), the disputed terms will be referred to and finally resolved [***]. 

4.4.    [***] 

(a)    Following selection of a Product Candidate pursuant to Section 4.1(a) of the A&R Option Agreement,
AstraZeneca will provide to Moderna, information regarding the scope and substance of its anticipated clinical Development and Commercialization activities requiring Moderna mRNA API for such Product Candidate (assuming that it becomes an Optioned
Product Candidate) (“AstraZeneca Anticipated Requirements”). At the first meeting of the JSC following Moderna’s receipt of the AstraZeneca Anticipated Requirements for an Product Candidate, Moderna will [***]. 

(b)    During the Term (and thereafter during the term of any Master Supply Agreement), Moderna will [***]. 

(c)    In the event that AstraZeneca, at any time in good faith, asserts that [***]. 

4.5.    Technology Transfer. Promptly after the occurrence of any Triggering Event, Moderna will provide
written notice thereof to AstraZeneca. After receipt of such notice, or after becoming aware of the occurrence of any Triggering Event, AstraZeneca will notify Moderna by written notice whether the rights and obligations under this Section 4.5
and Section 4.6 will apply to [***]; provided, that AstraZeneca may not elect to have the rights and obligations under this Section 4.5 and Section 4.6 apply to clause (b) under the following circumstances: (i) [***] and
(iii) [***], in which case [***] will apply, unless and until another Triggering Event occurs (the Moderna mRNA API(s) that are the subject of the transfer [***], the “Transferred API(s)”). Within [***] days of a Triggering Event,
Moderna will, and will cause its Affiliates and its manufacturers to, [***]. Without limiting the generality of the foregoing, with respect to each Transferred API [***] with respect to which AstraZeneca requests and is entitled to a technology
transfer, Moderna and its Affiliates will, and Moderna will [***], at AstraZeneca’s expense: 
 (a)    make
available to AstraZeneca [***] a copy of [***] (the “Manufacturing Know-How”); 

(b)    cause appropriate employees and representatives of Moderna and its Affiliates and [***] to [***]; 

(c)    take such steps as are [***]; 

(d)    upon AstraZeneca’s request, [***]; 

(e)    upon AstraZeneca’s request, [***]; and 

(f)    provide such other assistance as AstraZeneca may reasonably request to enable AstraZeneca or its designee to
Manufacture the Transferred APIs [***] in accordance with the applicable Specifications, including [***]. 

  
 25 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 Except as set forth above, [***] in connection with such technology transfer, and AstraZeneca will be [***]
in connection with such technology transfer. AstraZeneca and its Third Party manufacturer may only use the Manufacturing Know-How provided to AstraZeneca pursuant to this Section 4.5 in support of
Manufacturing the Transferred API(s) for so long as it elects (subject to the last sentence of this paragraph) and solely in accordance with the Transaction Agreements, and will not use any such Manufacturing
Know-How for any other reason or for any other product or product candidate (or intermediate or component thereof). [***] Following the completion of the technology transfer for the Transferred API(s),
AstraZeneca will notify Moderna regarding whether, for how long and to what extent it would expect to continue to purchase the Transferred API(s) from Moderna if problems leading to the Triggering Event were rectified. 

4.6.    [***] 

4.7.    Triggering Events. For the purposes of this Agreement [***], “Triggering Event” means:

 (a)    [***]; 

(b)    [***]; 

(c)    [***]; 

(d)    [***] 

(e)    [***]; or 

(f)    [***]. 

4.8.    Force Majeure. In the case of a force majeure event described in Section 11.8 related to Manufacturing
hereunder by or on behalf of Moderna or any force majeure event under any Master Supply Agreement that causes or is likely to cause an inability or materially reduced ability to supply Moderna mRNA API to AstraZeneca hereunder or thereunder, the
Parties agree to negotiate in good faith the most optimal manner in which to overcome such inability or materially reduced ability as promptly as practical, taking into account cost and quality. If the Parties agree that such inability or material
reduced ability would be more expediently remedied, taking into account cost and quality, if AstraZeneca assumed responsibility for such Manufacturing, then the Parties will agree in writing on a plan for such assumption, consent not to be
unreasonably withheld. 
 4.9.    Manufacturing Know-How Confidentiality.
In addition to the provisions of Section 7, AstraZeneca recognizes that maintaining the confidentiality and trade secret nature of the Manufacturing Know-How requires an even higher level of vigilance
than other Confidential Information, and agrees to (a) maintain in confidence Manufacturing Know-How with the same degree of care that AstraZeneca uses to protect its own like information,
(b) strictly limit access to and use of Manufacturing Know-How to employees, representatives, consultants and contractors of AstraZeneca, its Affiliates and its designated Third Party contract
manufacturers with a need to know such information, and (c) use Manufacturing Know-How only for producing Moderna mRNA API in accordance with a license granted by Moderna and for no other purpose.

  
 26 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
AstraZeneca will ensure that any person having access to the Manufacturing Know-How will be made aware of its highly confidential nature and will agree to
be bound by confidentiality terms no less stringent than those in this Agreement. 
 4.10.    Preparation of CMC
Section and DMF. If not previously prepared and filed, Moderna will, at AstraZeneca’s request, prepare and file with Regulatory Authorities a DMF and provide such other information and assistance as AstraZeneca may reasonably require
in connection with the completion of and submission of applications for Regulatory Approvals for Products. AstraZeneca may refer to such DMF in any filing made in connection with obtaining or maintaining a Regulatory Approval for a Product. Moderna
will be responsible for assuring that during any period in which Moderna has a supply obligation to AstraZeneca for mRNA API, such DMF will be in the form appropriate for filing with the Regulatory Authorities in the United States, the European
Union, Japan and such other countries as requested by AstraZeneca. Moderna will, on written request by AstraZeneca or its Affiliate or Sublicensee, provide to the requesting party and to any specified Regulatory Authority a letter, in the form
reasonably required by the requesting party, acknowledging that the requesting party has a right of reference to any such DMF. [***] 

5.    Regulatory Responsibilities. 

5.1.    In General. As set forth in greater detail below in this Section 5, AstraZeneca will lead and have sole
control of all regulatory efforts for Collaboration mRNA Constructs, Product Candidates, and Products worldwide, including with respect to preparing and filing the relevant Regulatory Filings and all communications with Regulatory Authorities. 

5.2.    Regulatory Filings. AstraZeneca will be responsible for preparing and submitting all Regulatory Filings
related to Collaboration mRNA Constructs, Product Candidates, and Products, including all applications for Regulatory Approval. All applications for Regulatory Approval, the Regulatory Approvals, and other Regulatory Filings (including all INDs)
relating to Collaboration mRNA Constructs, Product Candidates, and Products will be the property of AstraZeneca and held in the name of AstraZeneca or its designees. 

5.3.    Interactions with Regulatory Authorities. AstraZeneca will have the sole right to conduct all
communications with the Regulatory Authorities, including all meetings, conferences and discussions (including advisory committee meetings), with regard to Collaboration mRNA Constructs, Product Candidates, and Products in the Territory. 

5.4.    Moderna Regulatory Responsibilities Related to Manufacture. Consistent with the provisions of
Section 4.10, Moderna will, at its sole cost and expense, obtain and maintain all approvals, licenses, registrations, or authorizations (other than the Regulatory Approval for a Product) that are necessary or useful in connection with the
Manufacture of Collaboration mRNA Constructs, Product Candidates, and Products by or on behalf of Moderna. In addition, [***], prepare the Chemistry, Manufacturing, and Controls (“CMC”) and other Manufacturing provisions with
respect to all Regulatory Filings for, or that are otherwise necessary to obtain and maintain, Regulatory Approvals for the Products, including with respect to any Manufacture and supply of Collaboration mRNA Constructs, Product Candidates, and
Products by or on behalf of Moderna pursuant to Section 4, including any amendments with respect thereto [***]. As set forth in greater detail in Section 4.10, the CMC section of a Regulatory Approval for a Product may reference
Moderna’s DMF for such Product. 

  
 27 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 5.5.    Cooperation. Without limiting the provisions of
Section 5.4, during the Services Program Term, Moderna will cooperate with any reasonable requests for assistance from AstraZeneca with respect to obtaining any Regulatory Approval of Collaboration mRNA Constructs, Product Candidates, and
Products and maintaining any Regulatory Approval of Collaboration mRNA Constructs, Product Candidates, and Products that is held by AstraZeneca, including by: [***]. Assistance provided by Moderna to AstraZeneca pursuant to this Section 5.5
[***]. An estimate of such costs and expenses will be provided to AstraZeneca before the initiation of any agreed work. 

6.    Payment. 

6.1.    Up-Front Payment. AstraZeneca paid to Moderna within [***] Business
Days of the Implementation Date a one-time payment of [***] (the “Upfront Payment”). The (a) Upfront Payment and (b) fees payable by AstraZeneca pursuant to Sections 2.3(c) and
2.8(a) and Section 4 are paid by AstraZeneca in consideration for the Services to be performed by, and the Materials to be provided by, Moderna under this Agreement, and will be non-refundable and non-creditable and not subject to set-off (except for those payments under the foregoing clause (b), which payments will be subject to Section 11.17). 

6.2.    Reports; Payments. Moderna will furnish to AstraZeneca and the JSC a written report, after the end of each
[***], showing the amount of [***], in each case, incurred by Moderna for such [***], which report will be furnished within [***] of the end of [***]. The JSC will review and approve any such report within [***] of receipt thereof. With respect to
amounts invoiced by Moderna and payable by AstraZeneca under any Transaction Agreement, Moderna will submit an invoice in a form reasonably acceptable to AstraZeneca. 

6.3.    Records and Audits. Moderna will keep (and cause its Affiliates to keep) adequate books and records of
accounting that fairly reflect the FTE Costs, Patent Costs, and the budgeted out-of-pocket costs explicitly set forth in the Services Plan, all in sufficient detail to
confirm the accuracy of any payments required or made under the Transaction Agreements. Such books and records will be maintained by Moderna for at least [***] from the date of creation. Upon reasonable prior written notice to Moderna, such records
of Moderna and its Affiliates will be open for inspection during normal business hours by independent accountants selected by AstraZeneca and reasonably acceptable to Moderna and not paid in whole or in part by a contingent fee arrangement, which
such accountants will be obliged to execute a reasonable confidentiality agreement prior to commencing any such inspection or audit), for the purpose of verifying the accuracy of any payments required or made hereunder or confirming such rates or
prices. All such inspections may be made, at reasonable times mutually agreed by the Parties, no more than once in any [***] period and going back no more than [***] after receipt of the respective invoice and report. The cost of this examination
will be borne by AstraZeneca, unless the audit reveals a variance of more than [***] from the reported amounts for a calendar year, in which case Moderna will bear the reasonable
out-of-pocket cost of the audit; provided, such variance exceeds [***] dollars [***]. If such audit concludes that additional payments were owed or that excess
payments were made during such period, AstraZeneca will pay such additional amounts owed to Moderna and Moderna will pay the amount of any such excess payments to AstraZeneca. 

  
 28 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 7.    Confidentiality. 

7.1.    Confidential Information. 

(a)    Confidential Information. Each Party (“Disclosing Party”) may have disclosed or will
disclose to the other Party (“Receiving Party”), and Receiving Party may acquire during the course and conduct of activities under the Transaction Agreements, certain proprietary or confidential information of Disclosing Party. The
term “Confidential Information” means (i) all Materials (excluding any Moderna mRNA API supplied to AstraZeneca pursuant to Section 4) and (ii) all ideas and information of any kind, whether in written, oral,
graphical, machine-readable or other form, whether or not marked as confidential or proprietary, which are transferred, disclosed or made available to Receiving Party by Disclosing Party or at the request of Receiving Party, including any of the
foregoing of Third Parties. Without limiting the foregoing, [***] will be treated as Confidential Information of both Parties. 

(b)    Restrictions. During the Term and for [***] thereafter, Receiving Party will, and will cause its Affiliates
and their respective officers, directors, employees and agents to, keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information (though no less
than reasonable care); provided, that the foregoing obligation will apply to any Confidential Information that constitutes a trade secret for so long as such Confidential Information is afforded trade secret protection under applicable Law.
Receiving Party will not use, and will cause its Affiliates and their respective officers, directors, employees and agents not to use, Disclosing Party’s Confidential Information except for in connection with the performance of its obligations
and exercise of its rights under the Transaction Agreements. Receiving Party has the right to disclose Disclosing Party’s Confidential Information without Disclosing Party’s prior written consent (such consent not to be unreasonably
withheld, delayed or conditioned), to the extent and only to the extent reasonably necessary or useful, to Receiving Party’s Affiliates and their employees, subcontractors, sublicensees, consultants or agents who have a need to know such
Confidential Information in order to perform its obligations and exercise its rights under the Transaction Agreements and who are required to comply with restrictions on use and disclosure similarly restrictive as those in this Section 7.1(b).
Receiving Party will use [***] to cause those entities and persons to comply with such restrictions on use and disclosure. Notwithstanding the foregoing sentence, Receiving Party assumes responsibility for those entities and persons maintaining
Disclosing Party’s Confidential Information in confidence and using same only for the purposes described herein. 

(c)    Exceptions. Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the
Disclosing Party’s Confidential Information set forth in Section 7.1(b) will not apply to the extent that Receiving Party can demonstrate that the Disclosing Party’s Confidential Information: (i) was known to Receiving Party or
any of its Affiliates prior to the time of disclosure; (ii) is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates; (iii) is obtained by Receiving Party or any of its Affiliates from a Third
Party under no obligation of confidentiality to Disclosing Party; or (iv) has been independently developed by employees, subcontractors, consultants or agents of Receiving Party or any of its 

  
 29 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
Affiliates without the aid, application or use of Disclosing Party’s Confidential Information, as evidenced by contemporaneous written records. Notwithstanding the foregoing, (A) any
Confidential Information will not be deemed to be within the foregoing exceptions merely because such information is embraced by more general information in the public domain or in the possession of the Receiving Party or any of its Affiliates, and
(B) any combination of features will not be deemed to be within the foregoing exceptions merely because individual features are in the public domain or in the possession of the Receiving Party or any of its Affiliates, but only if the
combination itself and its principle of operation are in the public domain or in the possession of the Receiving Party or any of its Affiliates. 

(d)    Permitted Disclosures. Receiving Party may disclose Disclosing Party’s Confidential Information to the
extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 
 (i)    in order
to comply with applicable Law or the rules of any securities exchange or with a legal or administrative proceeding; 

(ii)    in connection with (A) prosecuting or defending litigation or (B) Prosecuting or Maintaining Patents for
Collaboration Technology; provided, [***]; 
 (iii)    in connection with exercising any rights or other licenses
under the Transaction Agreements, including with respect to any Joint Technology; 
 (iv)    in the case of AstraZeneca
to [***]; 
 (v)    in the case of AstraZeneca, [***]; 

(vi)    (A) in the case of Moderna, [***]; 

(vii)    in the case of Moderna, [***]; and 

(viii)    in the case of Moderna, [***]. 

In the case of a disclosure pursuant to (A) Sections [***], where reasonably possible, Receiving Party will notify Disclosing Party of Receiving
Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure [***], and (B) with respect to [***], each of those named people and entities are required to [***]. 

7.2.    Publications. The Parties may desire to publish in scientific journals and present at scientific
conferences the results of the Services Program, subject to the following process. Notwithstanding anything to the contrary herein, either Party may propose publication of the results of the Services Program following scientific review by the JSC
(if in force); provided, that no such publication will be made without written approval by Moderna and AstraZeneca. After receipt of the proposed publication by both AstraZeneca and Moderna, such written approval or disapproval will be
provided within [***] days. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of Patent applications, therefore the Parties agree to review and consider delay of publication and
filing of patent applications under certain circumstances for a reasonably limited period of time (including 

  
 30 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
as set forth in Section 10.2 of the A&R Option Agreement). Once publications have been reviewed by each Party and have been approved for publication, the same publications
do not have to be provided again to the other Party for review for a later submission for publication. Expedited reviews for abstracts or poster presentations may be arranged if mutually agreeable to the Parties. Each Party will acknowledge the
other Party’s technical, non-financial contributions in any such publication. For the avoidance of doubt, the foregoing requirements and restrictions will not apply with respect to either Party’s
proposed publication of results of any work performed with respect to any Discontinued Target. 
 7.3.    Terms of
this Agreement; Publicity. 
 (a)    Restrictions. 

(i)    The Parties agree that the terms of the Transaction Agreements will be treated as Confidential Information of both
Parties, and thus may be disclosed only as permitted by Section 7.1(d). Each Party will also be permitted to disclose the terms of this Agreement (including the Exhibits and Schedules hereto) and any executed Transaction Agreement, in each case
under appropriate confidentiality provisions, on a need to know basis, to [***]; provided, that (A) the disclosing Party agrees to redact information that it reasonably believes is not relevant to the proposed transaction, and
(B) [***] may be disclosed to any of the foregoing [***] only after [***]. 
 (ii)    [***] Except as required by
Law, each Party agrees not to issue any press release or public statement disclosing information relating to the Transaction Agreements, the transactions contemplated hereby or thereby or any of the terms hereof or thereof without the prior written
consent of the other Party (such consent not to be unreasonably withheld, delayed or conditioned), or as such consent may be obtained in accordance with Section 7.3(c). [***] 

(b)    Securities Filings. Each Party acknowledges and agrees that the other Party may submit the Transaction
Agreements (including for clarity, the Exhibits and Schedules hereto and thereto) to the United States Securities and Exchange Commission (the “SEC”) or any other securities exchange and if a Party does submit the Transaction
Agreements to the SEC or any other securities exchange, such Party agrees to consult with the other Party with respect to the preparation and submission of, a confidential treatment request for the Transaction Agreements. If a Party is required by
Law to make a disclosure of the terms of the Transaction Agreements in a filing with or other submission to the SEC or any other securities exchange, and (i) such Party has provided copies of the disclosure to the other Party as far in advance
of such filing or other disclosure as is reasonably practicable under the circumstances, (ii) such Party has promptly notified the other Party in writing of such requirement and any respective timing constraints, and (iii) such Party has
given the other Party a reasonable time under the circumstances from the date of notice by such Party of the required disclosure to comment upon, request confidential treatment or approve such disclosure, then such Party will have the right to make
such public disclosure at the time and in the manner reasonably determined by its counsel to be required by Law. Notwithstanding anything to the contrary herein, it is hereby understood and agreed that if a Party seeking to make a disclosure as set
forth in this Section 7.3(b), and the other Party provides comments within the respective time periods or constraints specified herein or within the respective notice, the Party seeking to make such disclosure or its counsel, as the case may
be, will 

  
 31 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
in good faith (A) consider incorporating such comments and (B) use reasonable efforts to incorporate such comments, limit disclosure or obtain confidential treatment to the extent
reasonably requested by the other Party. 
 (c)    Press Releases. Neither Party may issue any press release or
make any other public announcement or statement concerning the Transaction Agreements, the transactions contemplated hereby or thereby or the terms hereof or thereof, without the prior written approval of the other Party, except as may be required
by applicable Law. In the event either Party (the “Issuing Party”) desires to issue a press release or other public statement disclosing information relating to the Transaction Agreements, the transactions contemplated hereby
or thereby or the terms hereof or thereof, the Issuing Party will provide the other Party (the “Reviewing Party”) with a copy of the proposed press release or public statement (the “Release”) and seek the
Reviewing Party’s prior written consent; provided, that to the extent the press release or a public statement only includes the facts and under the circumstances described in Section 7.3(a)(i) and (a)(ii), the Reviewing Party may
not withhold, delay or condition its consent. The Issuing Party will specify with each such Release, taking into account the urgency of the matter being disclosed, a reasonable period of time within which the Receiving Party may provide any comments
on such Release. If the Receiving Party provides any comments, the Parties will consult on such Release and work in good faith to prepare a mutually acceptable Release. Either Party may subsequently publicly disclose any information previously
contained in any Release so consented to. 
 7.4.    Relationship to the Confidentiality Agreement. This
Agreement supersedes the Confidentiality Agreement; provided, that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed “Confidential Information” hereunder and will be subject to
the terms and conditions of this Agreement. 
 8.    Representations and Warranties; Limitations of Liability; Indemnification.

 8.1.    Representations and Warranties of Each Party. Each Party represents and warrants to the other as of the
Signing Date and the Amendment Effective Date that: 
 (a)    Such Party is duly organized, validly existing and in good
standing under the laws of the jurisdiction in which it is organized. 
 (b)    Such Party (i) has the legal right
and power to enter into this Agreement, to extend the rights granted or to be granted to the other in this Agreement, and to fully perform its obligations hereunder, and (ii) has taken all requisite action on its part to authorize the execution
and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation, enforceable against such Party in
accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization or other laws affecting creditors’ rights generally and by general equitable principles. 

(c)    Neither such Party nor its Affiliates has been debarred or is subject to debarment. Neither it nor its Affiliates
will use in any capacity, in connection with the services to be performed under the Transaction Agreements, any person who has been debarred pursuant to Section 306 of 

  
 32 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
the FFDCA, or who is the subject of a conviction described in such section. In addition, neither it nor its Affiliates has used in any capacity, in connection with any Development activities with
respect to the mRNA Technology or any Polypeptide carried out prior to the Signing Date, any person who has been debarred or was the subject of a conviction described in Section 306. Such Party agrees to inform the other Party in writing
immediately if it or any person who is performing services under the Transaction Agreements is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim, investigation or legal or administrative
proceeding is pending or, to the best of such Party’s or its Affiliates’ Knowledge, is threatened, relating to the debarment or conviction of such Party or any person performing services under the Transaction Agreements, or if such Party
becomes aware that it or any person performing Development activities with respect to an mRNA Construct, Polypeptide, Product Candidate or Product carried out prior to the Signing Date was debarred or was the subject of a conviction described in
Section 306. 
 (d)    All necessary consents, approvals and authorizations of all governmental authorities and
other Persons required to be obtained by such Party to enter into, or perform its obligations under, this Agreement have been obtained. 

(e)    The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder
(i) will not conflict with or violate any requirement of applicable Law or orders of governmental bodies except as individually or in the aggregate would not be reasonably expected to have a material adverse effect on or a material adverse
change in the ability of such Party to perform its obligations under or with respect to this Agreement; and (ii) do not conflict with, or constitute a default under, any contractual obligation of such Party, except as individually or in the
aggregate would not have a material adverse effect on or a material adverse change in the ability of such Party to perform its obligations under or with respect to this Agreement. 

8.2.    Disclaimers. Without limiting the respective rights and obligations of the Parties expressly set forth
herein, each Party specifically disclaims any guarantee that the Services Program or an Optioned Product Candidate will be successful, in whole or in part. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT OR THE OTHER TRANSACTION AGREEMENTS,
THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO ANY MODERNA TECHNOLOGY, PRODUCT CANDIDATES, MATERIALS, INCLUDING WARRANTIES OF VALIDITY OR ENFORCEABILITY OF ANY PATENTS, TITLE,
QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, PERFORMANCE, AND NONINFRINGEMENT OF ANY THIRD PARTY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS. 

8.3.    No Consequential Damages. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR THE OTHER TRANSACTION AGREEMENTS,
EXCEPT FOR DAMAGES DUE TO THE FRAUD OR WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF THE LIABLE PARTY, NEITHER PARTY WILL BE LIABLE TO THE OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT OR THE OTHER
TRANSACTION AGREEMENTS FOR ANY INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH PARTY HAS BEEN INFORMED OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, THAT THIS SECTION 8.3 WILL NOT APPLY TO THE
PARTIES’ INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER SECTION 8.5. 

  
 33 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 8.4.    Performance by Others. Subject to Sections 2.10 (in the
case of subcontractors) and 7.1(b), the Parties recognize that each Party may perform some or all of its obligations under this Agreement through Affiliates and permitted subcontractors; provided, that each Party will remain responsible and
liable for the performance by its Affiliates and permitted subcontractors and will cause its Affiliates and permitted subcontractors to comply with the provisions of this Agreement in connection therewith. 

8.5.    Indemnification. 

(a)    Indemnification by AstraZeneca. AstraZeneca will indemnify Moderna, its Affiliates and their respective
directors, officers, employees, Third Party licensors under the Existing In-License Agreements and agents, and their respective successors, heirs and assigns (collectively, “Moderna
Indemnitees”), and defend and save each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in
connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Third Party Claims”) arising from or occurring as a result of: [***]; provided, that AstraZeneca will not be obligated to
indemnify Moderna Indemnitees for any Losses to the extent that such Losses arise as a result of gross negligence or willful misconduct on the part of a Moderna Indemnitee. 

(b)    Indemnification by Moderna. Moderna will indemnify AstraZeneca, its Affiliates and their respective
directors, officers, employees and agents, and their respective successors, heirs and assigns (collectively, “AstraZeneca Indemnitees”), and defend and save each of them harmless, from and against any and all Losses in connection
with any and all Third Party Claims arising from or occurring as a result of: [***]; provided, that Moderna will not be obligated to indemnify AstraZeneca Indemnitees for any Losses to the extent that such Losses arise as a result of
(1) gross negligence or willful misconduct on the part of an AstraZeneca Indemnitee or (2) [***]. 

(c)    Notice of Claim. All indemnification claims provided for in Section 8.5(a) and 8.5(b) will be made
solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party will promptly notify the indemnifying Party (an “Indemnification Claim Notice”) of any Losses or the discovery of any fact upon
which the Indemnified Party intends to base a request for indemnification under Section 8.5(a) or 8.5(b), but in no event will the indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each
Indemnification Claim Notice must contain a description of the claim and the nature and estimated amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party will furnish promptly to the
indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. 

  
 34 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 (d)    Defense, Settlement, Cooperation and Expenses. 

(i)    Control of Defense. At its option, the indemnifying Party may assume the defense of any Third Party Claim by
giving written notice to the Indemnified Party within [***] days after the indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the indemnifying Party will not be construed as
an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor will it constitute a waiver by the indemnifying Party of any defenses it may assert against the Indemnified
Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the indemnifying Party (the
indemnifying Party will consult with the Indemnified Party with respect to a possible conflict of interest of such counsel retained by the indemnifying Party). In the event the indemnifying Party assumes the defense of a Third Party Claim, the
Indemnified Party will immediately deliver to the indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the indemnifying Party assume the
defense of a Third Party Claim, except as provided in Section 8.5(d)(ii), the indemnifying Party will not be liable to the Indemnified Party for any legal costs or expenses subsequently incurred by such Indemnified Party in connection with the
analysis, defense or settlement of the Third Party Claim. [***] 
 (ii)    Right to Participate in Defense.
Without limiting Section 8.5(d)(i), any Indemnified Party will be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, that such employment
will be at the Indemnified Party’s own cost and expense unless [***]. 
 (iii)    Settlement. With respect
to any Third Party Claims that relate solely to the payment of money damages in connection with a Third Party Claim and that will not result in the Indemnified Party’s becoming subject to injunctive or other relief or otherwise adversely
affecting the business of the Indemnified Party in any manner, and as to which the indemnifying Party will have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the indemnifying Party will have the sole right to
agree to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, will deem appropriate. With respect to all other Losses in connection with Third Party
Claims, where the indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 8.5(d)(i), the indemnifying Party will have authority to agree to the entry of any judgment, enter into any settlement or otherwise
dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (such consent not to be unreasonably withheld, delayed or conditioned). The indemnifying Party will not be liable for any settlement or other disposition of
a Loss by an Indemnified Party that is reached without the prior written consent of the indemnifying Party. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnified Party will admit any
liability with respect to or settle, compromise or discharge, any Third Party Claim without the prior written consent of the indemnifying Party, such consent not to be unreasonably withheld, delayed or conditioned. 

(iv)    Cooperation. If the indemnifying Party chooses to defend or prosecute any Third Party Claim, the
Indemnified Party will, and will cause each other Indemnified Party to, cooperate in the defense or prosecution thereof and will furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation will include access during normal business hours afforded to indemnifying Party to, and reasonable

  
 35 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnified Parties and other employees and agents available on a
mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the indemnifying Party will reimburse the Indemnified Party for all its reasonable out-of-pocket costs and expenses in connection therewith. 
 (v)    Costs
and Expenses. Except as provided above in this Section 8.5(d), the reasonable and verifiable costs and expenses, including attorneys’ fees and expenses, incurred by the Indemnified Party in connection with any claim will be reimbursed
on a Calendar Quarter basis by the indemnifying Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the indemnifying Party is ultimately
held not to be obligated to indemnify the Indemnified Party. 
 8.6.    Insurance. Each Party will maintain at
its sole cost and expense, an adequate liability insurance or self-insurance program (including product liability insurance) to protect against potential liabilities and risk arising out of activities to be performed under the Transaction
Agreements, and any agreement related hereto and upon such terms (including coverages, deductible limits and self-insured retentions) as are customary in the U.S. pharmaceutical industry, or, if such activities are conducted outside the U.S., as are
customary in such country, for the activities to be conducted by such Party under the Transaction Agreements. The coverage limits set forth herein will not create any limitation on a Party’s liability to the other under the Transaction
Agreements. 
 9.    Term and Termination. 

9.1.    Term. This Agreement will take effect as of the Amendment Effective Date and on such date it will replace
and supersede the Original Services and Collaboration Agreement in its entirety; provided that [***]. Unless sooner terminated in accordance with the terms hereof or by mutual written consent, the term of this Agreement will be deemed to have
commenced on the Signing Date and continue for the Option Agreement Term (the “Term”). For the avoidance of doubt, the replacement and superseding of the Original Agreements will not relieve the Parties of any liability which
accrued prior to the Amendment Effective Date. 
 9.2.    Termination by Moderna for Breach. Moderna will have
the right to terminate this Agreement in full upon delivery of written notice to AstraZeneca in the event of any material breach by AstraZeneca of any terms and conditions of this Agreement [***]; provided, that to the extent that any such
breach is limited to Collaboration mRNA Constructs for a particular Research Polypeptide or Development Polypeptide, Moderna will have the right to terminate this Agreement only with respect to the Collaboration mRNA Constructs for such Research
Polypeptide or Development Polypeptide (as applicable), and (a) such Collaboration mRNA Constructs will become Discontinued Product Candidates, (b) the applicable Research Polypeptide or Development Polypeptide will become a Discontinued
Polypeptide and (c) the Research Target addressed by such Discontinued Polypeptide will become a Discontinued Research Target unless for such Research Target there is an Optioned Product Candidate [***] Development Polypeptide for such Research
Target. For clarity, for the purposes of such discontinuance, [***]. Notwithstanding the foregoing, any such termination under this Section 9.2 will not be effective if such breach has been cured within [***] days after written notice thereof
is given by Moderna to 

  
 36 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
AstraZeneca specifying the nature of the alleged breach (or, if such default cannot be cured within such [***]-day period, such longer period as reasonably
required to cure such breach; provided, that AstraZeneca commences actions to cure such default within such [***]-day period and thereafter diligently continues such actions); provided, that to
the extent such material breach involves the failure to make an undisputed payment when due, such breach must be cured within [***] days after written notice thereof is given by Moderna to AstraZeneca. [***] 

9.3.    Termination by AstraZeneca. 

(a)    Breach. AstraZeneca will have the right to terminate this Agreement in full upon delivery of written notice
to Moderna in the event of any material breach by Moderna of any terms and conditions of this Agreement [***]; provided, that to the extent that any such breach is limited to a particular Target, AstraZeneca will have the right to terminate
this Agreement only with respect to such Target, and such Target will become a Discontinued Target. Notwithstanding the foregoing, any such termination under this Section 9.3(a) will not be effective if such breach has been cured within [***]
days after written notice thereof is given by AstraZeneca to Moderna specifying the nature of the alleged breach (or, if such default cannot be cured within such [***]-day period, such longer period as
reasonably required to cure such breach; provided, that Moderna commences actions to cure such default within such [***]-day period and thereafter diligently continues such actions); provided,
that to the extent such material breach involves the failure to make an undisputed payment when due, such breach must be cured within [***] days after written notice thereof is given by AstraZeneca to Moderna. [***] 

(b)    Discretionary Termination. AstraZeneca will have the right to terminate this Agreement in full ninety
(90) days after delivery of written notice to Moderna if the Executive Officer of AstraZeneca concludes due to scientific, technical, regulatory or commercial reasons, including [***]. 

9.4.    Alternative to Termination. If AstraZeneca has the right to terminate this Agreement under
Section 9.3(a) (including expiration of all applicable cure periods thereunder), in lieu of exercising such termination right, AstraZeneca may elect once by written notice to Moderna before the end of such applicable cure period to have this
Agreement continue in full force and effect, in which case the following will apply: 
 (a)    starting immediately
after the end of such applicable cure period, any payments for Contingent Event Option Exercise Payment and Option Exercise Earn-Out payments payable under the A&R Option Agreement following such date that
AstraZeneca has the right to terminate this Agreement under Section 9.3(a) will be reduced by [***]; provided, that such reduction will not apply if and to the extent [***]; 

(b)    The procedures set forth in [***] will continue to apply. 

(c)    [***] 

(d)    AstraZeneca’s obligation to [***] will terminate; provided, that AstraZeneca will keep Moderna
reasonably informed of AstraZeneca’s Development activities under the Services Program and Development of Product Candidates in the Development Pool. 

  
 37 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 (e)    The following provisions will cease to apply: [***]. 

9.5.    Effects of Termination or Expiration. Upon termination or expiration of this Agreement for any
reason:  
 (a)    the Services Program will terminate and any Research Polypeptides will become
Discontinued Polypeptides (and Collaboration mRNA Constructs with respect thereto will become Discontinued Product Candidates); provided, for clarity, that, AstraZeneca will retain its rights and obligations under the A&R Option Agreement
to any Optioned Product Candidates (and associated Subject Constructs and Products) at the time of such termination unless AstraZeneca is in breach of the A&R Option Agreement with respect to such Optioned Product Candidates (and associated
Subject Constructs and Products) and the provisions of this Agreement relevant to the Parties’ on-going activities with respect to such and Optioned Product Candidates (and associated Subject Constructs
and Products)including Article 4 and Exhibit A-1 shall continue to apply; 

(b)    Moderna will return (or destroy or erase, as directed by AstraZeneca) all data, files, records and other materials
containing or comprising AstraZeneca’s Confidential Information. Notwithstanding the foregoing, (i) in respect of physical embodiments of information, Moderna will be permitted to retain one copy of such data, files, records, and other
materials for non-commercial archival purposes, and (ii) in respect of any information stored electronically or in other non-physical media, it will be sufficient
for Moderna to procure that access to such information is restricted to non-commercial archiving purposes only; 

(c)    except to the extent AstraZeneca has rights to continue to Exploit Product Candidates, Option Product Candidates or
Products pursuant to the Transaction Agreements, all documents relating solely to or necessary to Exploit Discontinued Product Candidates, as such items exist as of the effective date of such termination, will be assigned to Moderna, and AstraZeneca
will provide to Moderna one (1) copy of the foregoing; and 
 (d)    except as otherwise necessary to continue
exercising any ongoing licenses under the Transaction Agreements, the Parties will return (or destroy or erase, as directed by the other Party) all data, files, records and other materials containing or comprising the other Party’s Confidential
Information. Notwithstanding the foregoing, (i) in respect of physical embodiments of information, the Parties will be permitted to retain one copy of such data, files, records, and other materials for
non-commercial archival purposes, and (ii) in respect of any information stored electronically or in other non-physical media, it will be sufficient for such Party
to procure that access to such information is restricted to non-commercial archiving purposes only. 
 In the event
that Moderna terminates this Agreement with respect to a particular Research Polypeptide or Development Polypeptide pursuant to Section 9.2, the provisions of this Section 9.5 will apply only with respect to such Research Polypeptide or
Development Polypeptide. 
 9.6.    Survival. In addition to the consequences of expiration or termination set
forth in Section 9.5, the following provisions will survive termination or expiration of this Agreement: [***]. Termination or expiration of this Agreement will not relieve the Parties of any liability or obligation which accrued hereunder
prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or 

  
 38 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. All other rights and obligations will terminate upon
expiration of this Agreement. 
 9.7.    Integrated Agreements. The Parties acknowledge that the Transaction
Agreements, together, constitute an integrated set of agreements entered into as part of the same transaction that collectively govern the subject matter covered by the Transaction Agreements. Early termination of any one of the Transaction
Agreements without the others would fundamentally alter the intended allocation of rights and obligations intended by the Parties in entering into the Transaction Agreements. Thus, if a Party (or its bankruptcy trustee) has the right to reject any
of the Transaction Agreements under the U.S. Bankruptcy Code or any analogous provision under any other law in any country outside the United States, such Party (or the applicable bankruptcy trustee) will either reject all of the Transaction
Agreements or assume all of the Transaction Agreements, but may not reject one Transaction Agreement without rejecting the others. 

10.    Tax Treatment of Agreement. 

10.1.    [***] 

10.2.    [***] 

10.3.    Indirect Taxes. Notwithstanding anything to the contrary contained in this Section 10.3 or elsewhere
in this Agreement, the following will apply with respect to Indirect Taxes. All payments hereunder are exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any such payments, AstraZeneca will pay such Indirect Taxes at the
applicable rate in respect of any such payments following the receipt, where applicable, of an Indirect Taxes invoice issued by Moderna in respect of those payments, such Indirect Taxes to be payable on the due date of the payment of the payments to
which such Indirect Taxes relate or at the time such Indirect Taxes are required to be collected by Moderna, in the case of payment of Indirect Taxes to Moderna. The Parties will issue invoices for all goods and services supplied under this
Agreement consistent with Indirect Tax requirements, and to the extent any invoice is not initially issued in an appropriate form, AstraZeneca will promptly inform Moderna and will cooperate with Moderna to provide such information or assistance as
may be necessary to enable the issuance of such invoice consistent with Indirect Tax requirements. 
 10.4.    Import
Duties. The Parties will co-operate in accordance with applicable Laws to ensure where permissible no import duties are paid on imported materials supplied by Moderna on the terms set forth in this
Agreement. The Party responsible for shipping will value any such materials in accordance with applicable laws. 
 11.    General
Provisions. 
 11.1.    Dispute Resolution for the Transaction Agreements . 

(a)    Disputes. Disputes of any nature arising under, relating to, or in connection with the Transaction
Agreements (“Disputes”) will be resolved pursuant to this Section 11.1. 

  
 39 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 (b)    Dispute Escalation. In the event of a Dispute between the
Parties, the Parties will first attempt to resolve such dispute by negotiation and consultation between themselves or the JSC. In the event that such dispute is not resolved on an informal basis within [***] days from receipt of the written notice
of a Dispute, any Party may, by written notice to the other, have such dispute referred to the Executive Officers (or their designees, which designee is required to have decision-making authority on behalf of such Party), who will attempt to resolve
such Dispute by negotiation and consultation for a [***] day period following receipt of such written notice. 

(c)    Full Arbitration. In the event the Parties have not resolved such Dispute, other than a Continuation
Criteria Dispute, within [***] days of receipt of the written notice referring such Dispute to the Executive Officers, either Party may at any time after such [***]-day period submit such Dispute to be finally
settled by arbitration in accordance with the rules of the London Court of International Arbitration (the “LCIA”) in effect at the time of submission, as modified by this Section 11.1. The arbitration will be
governed by the Laws of the state of New York. The arbitration will be heard and determined by three (3) arbitrators who are judges or attorneys with relevant experience in the pharmaceutical and biotechnology industry, each of whom will be
impartial and independent. Each Party will appoint one arbitrator and the third arbitrator will be selected by the two Party-appointed arbitrators, or, failing agreement within [***] days following appointment of the second arbitrator by the LCIA.
Such arbitration will take place in Boston, Massachusetts. The arbitration award so given will be a final and binding determination of the dispute, will be fully enforceable in any court of competent jurisdiction, and will not include any damages
expressly prohibited by Section 8.3. Fees, costs and expenses of arbitration are to be divided by the Parties in the following manner: AstraZeneca will pay for the arbitrator it chooses, Moderna will pay for the arbitrator it chooses, and the
Parties will share payment for the third arbitrator. Except in a proceeding to enforce the results of the arbitration or as otherwise required by law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration
hereunder without the prior written consent of both Parties (each such consent not to be unreasonably withheld, delayed or conditioned). 

(d)    Injunctive Relief. Notwithstanding the dispute resolution procedures set forth in this Section 11.1, in
the event of an actual or threatened breach of the Transaction Agreements, the aggrieved Party may seek provisional equitable relief (including restraining orders, specific performance or other injunctive relief), without first submitting to any
dispute resolution procedures hereunder. 
 (e)    Tolling. The Parties agree that all applicable statutes of
limitation and time-based defenses (such as estoppel and laches) will be tolled while the dispute resolution procedures set forth in this Section 11.1 are pending, and the Parties will cooperate in taking all actions reasonably necessary to
achieve such a result. [***] 
 11.2.    Cumulative Remedies and Irreparable Harm. All rights and remedies of the
Parties hereunder will be cumulative and in addition to all other rights and remedies provided hereunder or available by agreement, at law or otherwise. Each Party acknowledges and agrees that breach of any of the terms or conditions of this
Agreement would cause irreparable harm and damage to the other and that such damage may not be ascertainable in money damages and that as a result thereof the non-breaching Party would be entitled to seek on
an interim basis from a court and on a permanent basis from an arbitral tribunal equitable or injunctive relief restraining any breach or 

  
 40 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 
future violation of the terms contained herein by the breaching Party without the necessity of proving actual damages or posting bond. Such right to equitable relief is in addition to whatever
remedies either Party may be entitled to as a matter of law or equity, including money damages. 
 11.3.    Business
Combination. Notwithstanding anything to the contrary herein or therein, for purposes of the Transaction Agreements, [***]. 

11.4.    Anti-Bribery and Corruption Compliance. 

(a)    Moderna agrees, on behalf of itself, its officers, directors and employees and on behalf of its Affiliates, agents,
representatives, consultants and subcontractors hired for activities undertaken for or in connection with the performance of the Transaction Agreements (together with Moderna, the “Moderna Representatives”) that for the performance
of its obligations hereunder, Moderna Representatives will not directly or indirectly pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to: 

(i)    any government or political party official, official of an international public organization, candidate for public
office or representative of other businesses or a person acting on behalf of any of the foregoing (each, a “Government Official”) in order to influence official action; 

(ii)    any Person (whether or not a Government Official) (A) to influence such Person to act in breach of a duty of
good faith, impartiality or trust (“acting improperly”), (B) to reward such Person for acting improperly, or (C) where such Person would be acting improperly by receiving the money or other thing of value; 

(iii)    any other Person while knowing or having reason to know that all or any portion of the money or other thing of
value will be paid, offered, promised or given to, or will otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of the Transaction Agreements;
or 
 (iv)    any Person to reward that Person for acting improperly or to induce that Person to act improperly. 

(b)    Moderna Representatives will not, directly or indirectly, solicit, receive or agree to accept any payment of money
or anything else of value in violation of the law, including the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering,
money laundering or terrorism (“Anti-Corruption Laws”). 
 (c)    Moderna acknowledges that its
undertakings given in Sections 11.4(a) and 11.4(b) are material to AstraZeneca in entering into a relationship with AstraZeneca. 

(d)    Moderna, on behalf of itself and its Moderna Representatives, represents and warrants to AstraZeneca that during
the Term and [***] thereafter, it will and will procure that its Moderna Representatives keep and maintain accurate books and reasonably detailed records in connection with the performance of its obligation under the Transaction Agreements including
all records required to establish compliance with Sections 11.4(a) and 11.4(b) above. 

  
 41 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 (e)    Moderna will promptly provide AstraZeneca with written notice of
the following events: (i) upon becoming aware of any breach or violation by it or its Moderna Representatives of any representation, warranty or undertaking set forth in Sections 11.4(a) and 11.4(b); and (ii) upon receiving a formal
notification that it is the target of a formal investigation by a Relevant Authority for a Material Anti-Corruption Law Violation or upon receipt of information from any of its Moderna Representatives connected with this Agreement that any of them
is the target of a formal investigation by a Relevant Authority for a Material Anti-Corruption Law Violation.  

(f)    During the Term and [***] thereafter, Moderna will for the purpose of auditing and monitoring the performance of
its compliance with the Transaction Agreements and particularly this Section 11.4 permit AstraZeneca, its Affiliates, any auditors of any of them and any Regulatory Authority to have access to any premises of Moderna or its Moderna
Representatives used in connection with the Transaction Agreements, together with a right to access personnel and records that relate to the Transaction Agreements. 

(g)    Moderna will be responsible for any breach of any representation, warranty or undertaking in this Section 11.4
or of the Anti-Corruption Laws by any of its Moderna Representatives. 
 (h)    Each Party may disclose the terms of the
Transaction Agreements or any action taken under this Section 11.4 to prevent a potential violation or continuing violation of applicable Anti-Corruption Laws, including the identity of the other Party and the payment terms, to any governmental
authority if such Party determines, upon advice of counsel, that such disclosure is necessary. 

11.5.    Relationship of Parties. Nothing in this Agreement is intended or will be deemed to constitute a
partnership, agency, employer-employee or joint venture relationship between the Parties. No Party will incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein. There are no express or
implied third party beneficiaries hereunder. 
 11.6.    Compliance with Law. Each Party will perform or cause to
be performed any and all of its obligations or the exercise of any and all of its rights hereunder in good scientific manner and in compliance with all applicable Law. 

11.7.    Data Privacy. Without prejudice to Section 11.6, notwithstanding any other term of the Transaction
Documents neither Party will, or will be required to, transfer to the other Party any information relating to an identified or identifiable (directly or indirectly) natural person (“Personal Data”) if either Party, acting
reasonably, determines that such transfer or any subsequent processing of such Personal Data would not comply with any applicable laws relating to the transfer and processing of such Personal Data. If the transfer of such Personal Data is otherwise
required by this Agreement, the Parties shall negotiate in good faith and seek to enter into such agreement as reasonably required to ensure that such transfer and subsequent processing does comply with such applicable laws. 

  
 42 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 11.8.    Force Majeure. Neither Party will be liable to the other
for failure of or delay in performing obligations set forth in this Agreement (other than any obligation to pay monies when due), and neither will be deemed in breach of such obligations, if such failure or delay is due to natural disasters or any
causes reasonably beyond the control of such Party; provided, that the Party affected will promptly notify the other of the force majeure condition and will exert reasonable efforts to eliminate, cure or overcome any such causes and to resume
performance of its obligations as soon as possible. 
 11.9.    Governing Law. This Agreement will be governed by
and construed in accordance with the Laws of the state of New York, without respect to its conflict of laws rules or principles that might otherwise refer construction or interpretation of this Agreement to the substantive Law of another
jurisdiction; provided, that any dispute relating to the scope, validity, enforceability or infringement of any Patents will be governed by, and construed and enforced in accordance with, the substantive Laws of the jurisdiction in which such
Patents apply. The Parties agree to exclude the application to this Agreement of the United Nations Convention on Contracts for the International Sale of Goods.  

11.10.    Counterparts; Facsimiles. This Agreement may be executed in one or more counterparts, each of which will
be deemed an original, and all of which together will be deemed to be one and the same instrument. Facsimile or PDF execution and delivery of this Agreement by either Party will constitute a legal, valid and binding execution and delivery of this
Agreement by such Party 
 11.11.    Headings. All headings in this Agreement are for convenience only and will
not affect the meaning of any provision hereof. 
 11.12.    Waiver of Rule of Construction. Each Party has had
the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement will be construed against the drafting party will not
apply. 
 11.13.    Interpretation. Whenever any provision of this Agreement uses the term “including”
(or “includes”), such term will be deemed to mean “including without limitation” (or “includes without limitations”). “Herein,” “hereby,” “hereunder,” “hereof” and other
equivalent words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which any such word is used. Except where the context otherwise requires, whenever used, the singular will include the plural, the
plural the singular, the use of any gender will be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Unless otherwise provided, all references to Sections, Schedules and Exhibits in this Agreement are to
Sections, Schedules and Exhibits of this Agreement. References to any Sections include Sections and subsections that are part of the related Section (e.g., a section numbered “Section 2.1” would be part of
“Section 2”, and references to “Section 2.1” would also refer to material contained in the subsection described as “Section 2.1(a)”). 

11.14.    Binding Effect. This Agreement will inure to the benefit of and be binding upon the Parties, their
Affiliates, and their respective lawful successors and assigns. 

  
 43 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 11.15.    Assignment. This Agreement may not be assigned by either
Party, nor may either Party delegate its obligations or otherwise transfer any rights created by this Agreement, except as expressly permitted hereunder or otherwise without the prior written consent of the other Party, which consent will not be
unreasonably withheld, delayed or conditioned; provided, that either Party may assign this Agreement to an Affiliate or to such Party’s successor in connection with the merger, consolidation, sale of all or substantially all of its
assets or that portion of its business pertaining to the subject matter of this Agreement, or any Business Combination of such Party. Notwithstanding the foregoing, neither Party may assign this Agreement unless such assignment also includes an
assignment of all of the Transaction Agreements other than an assignment with respect to a particular Optioned Product Candidate as permitted by the A&R Option Agreement, to the same Affiliate or Third Party successor, as applicable. The rights
and obligations of the Parties under this Agreement will be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein will be deemed to include the name of such
Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Section 11.15. 

11.16.    Notices. All notices, requests, demands and other communications required or permitted to be given
pursuant to this Agreement or the A&R Option Agreement will be in writing and will be deemed to have been duly given upon the date of receipt if delivered by hand, recognized international overnight courier, electronic transmission to email
address below (if any), or registered or certified mail, return receipt requested, postage prepaid to the following addresses: 
  

			
	If to Moderna:	 	Moderna Therapeutics, Inc.
	 	 	200 Technology Square
	 	 	Cambridge, MA MA 02139
		
	 	 	Attention: Stéphane Bancel, CEO
	 	 	Email:
		
	With copies to:	 	ModernaTX, Inc.
	 	 	200 Technology Square
	 	 	Cambridge, MA MA 02139
		
	 	 	Attention: Shaun Ryan, Deputy General Counsel
	 	 	Email: Shaun.Ryan@modernatx.com; legal@modernatx.com
		
	 	 	Goodwin|Procter LLP
	 	 	53 State Street
	 	 	Boston, MA 02109
	 	 	Attention: Kingsley Taft, Esq.
	 	 	Email: Ktaft@goodwinlaw.com
		
	If to AstraZeneca:	 	AstraZeneca AB
	 	 	Pepparredsleden 1
	 	 	S-431 83 Mölndal
	 	 	Attention: Senior Director, Innovative Medicines, iMed CVGI

  
 44 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

			
	With copies to:	 	AstraZeneca AB
	 	 	Pepparredsleden 1
	 	 	S-431 83 Mölndal
	 	 	Attention: Corporate Legal, Deputy General Counsel.
		
	 	 	Covington & Burling LLP
	 	 	265 Strand
	 	 	London WC2R 1BH
	 	 	Attention: Lucinda Osborne, Esq.
	 	 	Email: losborne@cov.com

 Either Party may change its designated address by notice to the other Party in the manner provided in this Section 11.16.

 Notwithstanding the foregoing, notification of the nomination of Polypeptides as “Research Polypeptides”, the exclusion of Research Targets
from the Services Program and notification of AstraZeneca’s determination that a Research Target has met the applicable Continuation Criteria may be made by each Party by e-mail from its Program Director
to the other Party’s Program Director using the then current e-mail addresses of the Program Directors. 

11.17.    Right to Set-Off. Except as otherwise set forth in this Agreement
or any Transaction Agreement, each Party has the right at all times to retain and set off against all amounts due and owing to the other Party as determined in a final judgment any damages recovered by such Party for any Losses incurred by such
Party. 
 11.18.    Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified only
by means of a written instrument signed by both Parties; provided, that any unilateral undertaking or waiver made by one Party in favor of the other will be enforceable if undertaken in a writing signed by the Party to be charged with the
undertaking or waiver. Any waiver of any rights or failure to act in a specific instance will relate only to such instance and will not be construed as an agreement to waive any rights or fail to act in any other instance, whether or not similar.

 11.19.    HSR Act Filings. The Parties acknowledge that HSR Act Filings (as defined in the Original
Services & Collaboration Agreement) were made in accordance with the Original Services and Collaboration Agreement. 

11.20.    Severability. In the event that any provision of this Agreement will, for any reason, be held to be
invalid or unenforceable in any respect, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provisions will be given no effect by the Parties and will not form
part of this Agreement, (b) all other provisions of this Agreement will remain in full force and effect, and (c) the Parties will negotiate in good faith to modify this Agreement to preserve (to the extent possible) their original intent

 11.21.    Entire Agreement. This Agreement and the other Transaction Agreements (and any agreements entered
into pursuant to the Original Agreements) are the sole agreements with respect to the subject matter and, except as provided in Section 9.1, supersede all other agreements and understandings between the Parties with respect to same (including
the Confidentiality Agreement). 
 [Remainder of this Page Intentionally Left Blank] 

  
 45 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 IN WITNESS WHEREOF, the Parties have caused this Amended and Restated Services and
Collaboration Agreement to be executed by their respective duly authorized officers as of the Amendment Effective Date. 
  

			
	MODERNATX, INC. 
		
	By:	 	 /s/ Stéphane Bancel

	 	 	(Signature)
	Name:	 	 Stéphane Bancel

	Title:	 	 CEO

	Date:	 	 June 15, 2018

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

			
	ASTRAZENECA AB
		
	By:	 	 /s/ Jesper Bergkvist

		 	(Signature)
	Name:	 	 Jesper Bergkvist

	Title:	 	 Legal Director

	Date:	 	 June 15, 2018

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 Exhibit A-1 

non-cGMP Moderna mRNA API Supply Terms 

[***] 
  

							
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  	[***]	  	[***]	  	[***]
				
	[***]	  		  		  	[***]

 [***] 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 Exhibit A-2 

cGMP Moderna mRNA API Supply Terms 
 [***]

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 Schedule 1.34 

Continuation Criteria 
 [***] 

 

			
	 [***]
	  	 [***]

		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
	[***]	  	[***]
		
	[***]	  	[***]

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 [***] 
  

			
	 [***]
	  	 [***]

		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 Schedule 1.100 

Moderna Patents as of the Signing Date 
  

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
		  		  		  		  	
					
		  		  		  		  	

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

					
	[***]	  	[***]	  	[***]	  	[***]	  	[***]

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 Schedule 2.12 

AstraZeneca Bioethics Policy 
 The
AstraZeneca Bioethics Policy is applicable to everyone involved in R&D activities including any third party who acts on our behalf. 
 AstraZeneca
Bioethics Policy defines the principles, behaviours and ethical standards governing our research and development worldwide. While many topics are covered by existing national laws and regulations, this policy sets out the commitment beyond ordinary
legal compliance of AstraZeneca and third parties acting on AstraZeneca’s behalf. Further information on Animal Care and Use at AstraZeneca is available on our web site (https://www.astrazeneca.com/content/dam/az/PDF/2016/Bioethics_policy.pdf)

  

	 	•	 	 [***] 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 Appendix A 

List of nominated Research Polypeptides as of the Amendment Effective Date 

[***] 

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

 [***] 
  

			
		  	[***]
	1.	  	
	2.	  	
	3.	  	
	4.	  	
	5.	  	
	6.	  	
	7.	  	
	8.	  	
	9.	  	
	10.	  	
	11.	  	
	12.	  	
	13.	  	
	14.	  	
	15.	  	

 [***] 
  

			
		  	[***]
	1.	  	[***]
	2.	  	
	3.	  	
	4.	  	
	5.	  	
	6.	  	
	7.	  	
	8.	  	
	9.	  	

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

			
	10.	  	
	11.	  	
	12.	  	
	13.	  	
	14.	  	
	15.	  	

 [***] 
  

			
		  	[***]
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	
	•	  	

 [***] 
  

			
		  	[***]
	1.	  	
	2.	  	

 A&R SERVICES AND COLLABORATION
AGREEMENT 
  

			
	3.	  	
	4.	  	
	5.	  	
	6.	  	
	7.	  	
	8.	  	
	9.	  	
	10.	  	
	11.	  	
	12.	  	
	13.	  	
	14.	  	
	15.	  	

 [***] 
  

			
		  	[***]
	1.	  	
	2.	  	
	3.	  	
	4.	  	
	5.	  	
	6.	  	
	7.	  	
	8.	  	
	9.	  	
	10.	  	
	11.	  	
	12.	  	
	13.	  	
	14.	  	
	15.EX-10.8

 Exhibit 10.8 

Patent Sublicense Agreement 

This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a
place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and ModernaTx, Inc., a Delaware corporation having a place of business at 320 Bent Street, Cambridge, MA 02141, USA (“Company”). This
Agreement is effective as of June 26, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”. 

BACKGROUND 
 WHEREAS, mRNA
RiboTherapeutics, Inc. (“mRNA RiboTherapeutics”) has an exclusive license from the Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”) for certain intellectual property
comprising patents, patent applications and technology relating to use of modified ribonucleic acid (RNA) technology which was developed by Drs. Drew Weissman and Katalin Kariko of Penn’s Perelman School of Medicine as described in [***], and
certain other intellectual property comprising patents, patent applications and technology relating to the modified RNA technology, inter alia, for reprogramming of mammalian cells to induced pluripotent stem cells, as described in [***], pursuant
to the Second Amended and Restated Patent License Agreement which became effective as of December 20, 2016 (the “Penn License Agreement”), under which Cellscript has a sublicense from mRNA RiboTherapeutics in certain fields of
use pursuant to the Amended and Restated Patent Sublicense Agreement which became effective as of December 20, 2016 (the “Cellscript Sublicense Agreement”), under which Cellscript has the right to further sublicense all or any
part of the rights granted to Cellscript to other parties; and 
 WHEREAS, Company desires a sublicense to the Patents Rights (as defined
below) from Cellscript for in vivo uses in humans and non-human animals and for certain other uses pertaining thereto and Cellscript is willing to grant to Company a sublicense to said intellectual
property for such uses under the terms and conditions herein; 
 NOW, THEREFORE, in consideration of the mutual obligations contained in
this Agreement, and intending to be legally bound, the Parties agree as follows: 
 1     SUBLICENSE 

1.1    Sublicense Grant. Cellscript hereby grants to Company and Company hereby accepts from Cellscript a worldwide,
non-exclusive sublicense under the Patent Rights during the Term to make, have made, import, use, offer for sale, sell and/or have sold Licensed Products according to the terms and conditions herein:
(1) in Field of Use B for all uses in the In Vivo Field of Use, including: (a) all therapeutic and prophylactic uses in humans; (b) all non-therapeutic and
non-prophylactic uses in humans; and (c) all uses, including therapeutic and prophylactic uses (e.g., Veterinary Products), in non-human animals; and (2) in
Field of Use A for internal research and screening uses, including [***], including for the Fields of Use in (1)(a) through (1)(c); ((1) and (2) collectively, the “Sublicensed Fields of Use”), as all said terms are defined in
Sections 1.2 and 6.1 herein (the “Sublicense”). The Sublicense includes the right for Company to grant sublicenses to its affiliates and Third Parties for all or any part of the rights and fields of use granted to Company, under
terms that are consistent with this Agreement. No other rights or licenses are granted by Cellscript to Company under this Agreement; [***]. 

  
 1 

 1.2    Related Definitions. 

Whenever the words or terms “comprising,” “containing,” “having,” “include,” includes,”
“including,” “such as,” “for example,” “an example,” “examples,” “e.g.,” “for further clarification” or the like are used in this Agreement, they shall be understood to be
followed by the words “without limitation” or “but without limitation”. The terms “a,” “an,” and “the” and the use of such terms or nouns in definitions in either the singular or the plural are to be
construed to cover both the singular and the plural unless otherwise noted. 
 “Licensed Products” means products that are
made, made for, used, imported, offered for sale or sold by Company or its Affiliates or Third Party sublicensees [***]. For clarity, Licensed Products includes any method, procedure or process, the use of which by Company or its Affiliates or Third
Party sublicensees, [***]. 
 “Exhibit A-1 Patent Rights” means all of Penn’s
patent rights represented by or issuing from: (a) the United States and PCT patents and patent applications listed in Exhibit A-1; (b) any continuation, divisional, reexamination, and re-issue applications of (a); and (c) any extensions and foreign counterparts of (a) or (b). 

“Exhibit A-2 Patent Rights” means all of Penn’s patent rights represented by or
issuing from: (a) the United States and PCT patents and patent applications listed in Exhibit A-2; (b) any continuation, divisional, reexamination, and re-issue
applications of (a); and (c) any extensions and foreign counterparts of (a) or (b). 
 “Patent Rights” means
Exhibit A-1 Patent Rights and/or Exhibit A-2 Patent Rights. 

“Affiliate” means a legal entity that is controlling, controlled by or under common control with Company and that has
executed either this Agreement, a sublicense for at least a portion of the rights granted to Company under this Agreement, or a written joinder agreement agreeing to be bound by all of the terms and conditions of this Agreement. The uncapitalized
term “affiliate” means, with respect to a first legal entity, any other legal entity that is controlling, controlled by or under common control with said first legal entity. For purposes of the definitions of “Affiliate”
and “affiliate” herein, the word “control” means (x) the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of a legal entity, (y) the right to receive fifty percent
(50%) or more of the profits or earnings of a legal entity, or (z) the right to determine the policy decisions of a legal entity. 

“Field of Use A” means and is limited to internal laboratory research or screening [***]. For clarity, Field of Use A
includes [***]. For further clarity, a party that has a sublicense in Field of Use A pertaining to a sublicensed therapeutic or prophylactic or diagnostic or prognostic use in Field of Use B shall have the right to [***]. 

[***] 
 “Field of Use
B” means the field other than Field of Use A and includes but is not limited to therapeutic, prophylactic, diagnostic, prognostic and cosmetic uses in humans and agricultural, animal improvement and veterinary uses in animals. For clarity,
Field of Use B includes any and all fields of use, including the In Vivo Field of Use and Ex Vivo Field of Use, other than for Field of Use A. 

“Fields of Use” means Field of Use A and Field of Use B. 

“Ex Vivo Field of Use” is a subfield of Field of Use A or Field of Use B wherein a product or method that is
covered by Patent Rights is used in cells, tissues or organs that are ex vivo or outside of a living human or animal body or organism, [***]. 

  
 2 

 “In Vivo Field of Use” is a subfield of Field of Use A or
Field of Use B wherein a product or method that is covered by Patent Rights is used in vivo, [***]. 
 “Diagnostic and
Prognostic Field of Use” is a subfield of use within Field of Use B wherein a product or service covered by Patent Rights is used for diagnosis, prognosis or testing of a human or non-human animal or
a sample therefrom in order to detect, identify, determine a cause, evaluate, analyze, understand, predict, rule in, or rule out a medical condition or disease or to predict an effect or response to treatment, and/or to monitor the effect of a
treatment of such medical condition or disease. [***] 
 “Veterinary Product” means a product that is covered by Patent
Rights which is used for the care, treatment, breeding or use of livestock or companion animals. 
 “Third Party” means any
person, corporation, partnership, association, consortium or business, legal or governmental entity other than Penn, Cellscript, Company or any of their respective affiliates. 

[***] 

1.3    Reservation of Rights by Penn. Penn reserves the right to use, and to permit other non-commercial entities to use, the Patent Rights for educational and non-commercial research purposes. 

1.4    U.S. Government Rights. The Parties acknowledge that the United States government retains rights in
intellectual property funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement that products,
which result from such intellectual property and are sold in the United States, must be substantially manufactured in the United States. 

1.5    Sublicense Conditions. Company’s right to extend any or all of the rights granted to Company by
Cellscript via a sublicense to affiliates or Third Parties is subject to each of the following conditions:  

1.5.1    Company will have the right to grant further sublicenses to its affiliates and to Third Parties (“sub-sublicensees”) that permit multiple levels of sublicensing, including in Third Party sub-sublicenses that permit further levels of sublicensing (e.g., to “sub-sub-sublicensees”). In each further sub-sublicense agreement to an affiliate or Third Party, Company will require the sub-sublicensee to comply with terms and conditions that are consistent with this Agreement, and in each agreement for further sublicensing (e.g., by a sub-sublicensee of
Company to a sub-sub-sublicensee), the party granting the further sublicense will require the party receiving the further sublicense to comply with terms and conditions
that are consistent with its sub-sublicense agreement from Company. Except when used to clarify the meaning of the different terms in this Section 1.5.1, the term sublicense in this Agreement includes any
permitted sub-sublicense, sub-sub-sublicense, etc. and the term sublicensee includes any permitted sub-sublicensee, sub-sub-sublicensee, etc. 
 1.5.2    Within
[***] days after Company enters into a sublicense agreement, Company will deliver to Cellscript a complete and accurate copy of the entire sublicense agreement written in the English language, provided that Company will have the right to redact the
terms and conditions of such sublicense agreement that are not necessary for Cellscript to confirm compliance with all terms and conditions required under this Sublicense, including Section 1.5 hereof. Cellscript’s receipt of the
sublicense agreement will not constitute a waiver of any right or obligation of Cellscript or of Company under this Agreement. 

  
 3 

 1.5.3    In the event that Company causes or experiences a Trigger Event
(as defined in Section 6.4), to the extent permissible by law, [***]. 
 1.5.4    Company’s execution of a
sublicense agreement will not relieve Company of any of its obligations under this Agreement. Company is primarily liable to Cellscript for any act or omission of a sublicensee that would be a breach of this Agreement if performed or omitted by
Company, and Company will be deemed to be in breach of this Agreement as a result of such act or omission. Upon learning of any such breach of this Agreement due to an act or omission of a sublicensee of Company, Company will [***]. Provided that
Company [***], a breach by said sublicensee shall not be considered a breach by Company that will be considered a cause for termination of this Agreement under Section 6.3. 

1.5.5    A sublicense granted by the Company or a further sublicensee thereof will not be assignable or transferable by
said sublicensee or further sublicensee thereof without the prior written consent of Cellscript, except to an affiliate of the sublicensee of Company or an affiliate of said further sublicensee thereof, or to a Third Party company that: (i) can
demonstrate based on reliable financial information that it has all technical knowledge, capabilities and/or financial resources needed to perform in all respects in the place and stead of said sublicensee or further sublicensee thereof;
(ii) agrees to assume all duties and responsibilities under the sublicense; [***]; and (v) agrees in writing to be bound by all of the terms and conditions of the sublicense and a copy of such written undertaking is promptly provided to
Company, which will provide a copy to Cellscript, which, in turn, will provide a copy to mRNA RiboTherapeutics. 

1.6    No License by Implication. Nothing in this Agreement confers by estoppel implication or otherwise, any
license or rights under any Penn patent other than rights granted under patents included in the Patent Rights and Exhibit D Patents, regardless whether such patents are dominant or subordinate to the Patent Rights and Exhibit D Patents. 

1.7    License to the Exhibit D Patents. Whereas Cellscript has an exclusive license from Penn for certain U.S.
patents and patent applications listed in Exhibit D hereto, including any continuation, divisional, reexamination, and re-issue applications and any patents or extensions of any of the foregoing (collectively
referred to as “Exhibit D Patents” herein), which Exhibit D Patents are not included in Patent Rights herein; and whereas, Company desires a sublicense to Exhibit D Patents in the Sublicensed Fields of Use during the Term and
Cellscript is willing to grant such a sublicense in the Sublicensed Fields of Use according to the terms and conditions herein, now, therefore, Cellscript hereby grants to Company and Company hereby accepts from Cellscript a limited worldwide, non-exclusive sublicense under Exhibit D Patents during the Term to make, have made, import, use, offer for sale, sell and/or have sold Licensed Products which are also covered by Exhibit D Patents, solely in the
Sublicensed Fields of Use, and according to the terms and conditions herein. The sublicense includes the right for Company to grant sublicenses to its affiliates and Third Parties for all or any part of the rights granted to Company in the
Sublicensed Fields of Use, under terms that are consistent with this Agreement. No other rights or licenses pertaining to Exhibit D Patents are granted by Cellscript to Company under this Agreement. [***] 

1.8    Relation of this Agreement to mRNA RiboTherapeutics Sublicense Agreement. Concurrent with the execution of this Agreement,
Company is entering into a separate sublicense agreement with mRNA RiboTherapeutics (the “mRNA RiboTherapeutics Sublicense Agreement”), pursuant to which mRNA RiboTherapeutics is granting Company a sublicense under Patent Rights
with respect to certain fields of use that are different from and are not included within the scope of the Sublicense granted to Company in this Agreement 

  
 4 

 2    DILIGENCE 

2.1    Development Plan and Sublicense Disclosure Report. By [***], Company will deliver to Cellscript: (1) a
copy of an annual development plan, including [***] and a summary of material development efforts for Licensed Products since the last development plan (“Development Plan”); [***] (2) a Sublicense Disclosure Report
(“SDR”), [***]. 
 2.2    Company’s Efforts. Company will use commercially reasonable
efforts to develop, commercialize, market and sell Licensed Products in the Sublicensed Fields of Use in a manner consistent with the Development Plan. In addition to Company’s own efforts to develop, commercialize, market and sell Licensed
Products, the efforts of other parties, including Affiliates, Third Party sublicensees, contractors, Third Parties funded by Company under a research or service agreement, and distributors, will also be deemed as efforts of Company. 

2.3    Diligence Events. Company, whether itself, or through its Affiliates, Third Party sublicensees, contractors,
or Third Parties funded by Company under a research or service agreement, will use commercially reasonable efforts to achieve each of the milestone diligence events by the applicable completion date listed in the table below for the first Licensed
Product for human therapeutic or prophylactic use in Field of Use B. Company will provide Cellscript with written notice within [***] days of first completion of each milestone diligence event for a Licensed Product for human therapeutic or
prophylactic use in Field of Use B by Company or an Affiliate or Third Party sublicensee. 
  

			
	 MILESTONE DILIGENCE EVENT
	  	COMPLETION
DATE
	 1. [***]
	  	[***]
	 2. [***]
	  	[***]
	 3. [***]
	  	[***]
	 4. [***]
	  	[***]
	 5. [***]
	  	[***]

 2.4    Diligence Resources. Until [***], Company will expend financial resources
for the development and commercialization of the Licensed Products in amounts not less than the diligence minimums specified in the table below (“Development Expenditures”) in each [***] period following the Effective Date.
Development Expenditures shall include all research and development expenditures directly relating to Licensed Products, including [***]. If Company’s total expenditures for development and commercialization of Licensed Products in any [***] do
not meet or exceed the applicable diligence minimum, then [***]. 
  

							
	 ANNIVERSARY:
	  	[***]	  	[***]	  	[***]
	 SUBLICENSE DILIGENCE FEE:
	  	[***]	  	[***]	  	[***]

  
 5 

 3    FEES AND ROYALTIES 

3.1    Sublicense Grant Fees. In partial consideration for the Sublicense, Company will pay to Cellscript: [***] a
non-refundable, non-creditable sublicense fee of twenty-two million U.S. dollars ($22,000,000) on [***] of 2019, [***]. 

3.2    Sublicense Maintenance Fees. In partial consideration of the Sublicense, Company will pay to Cellscript
[***] on each [***] occurring during the Term until the date of [***]. For clarity, the next annual sublicense maintenance fee under this Agreement is payable to Cellscript on [***]. 

3.3    Milestone Payments. In partial consideration of the Sublicense, promptly following the Effective Date,
Company will provide Cellscript with [***] and Company will pay to Cellscript within [***] after the Effective Date all [***]. Thereafter, in further partial consideration of the Sublicense, Company will pay to Cellscript the milestone payment
listed in Table A or Table C in this Section 3.3, as applicable, [***], regardless of whether the milestone is achieved by Company, an Affiliate or a Third Party sublicensee. Company will provide Cellscript with written notice within [***] days
after each milestone is achieved by Company or a sublicensee and Company will pay to Cellscript all applicable milestone payments owed therefor within [***] days of the end of the calendar quarter in which the milestone event is achieved. [***] 

[Remainder of Page Intentionally Left Blank] 

  
 6 

			
	 Section 3.3 Table A

MILESTONES for [***] [***]

	 MILESTONE EVENT
	  	Payment
to Cellscript
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 TOTAL
	  	$25,500,000

  

			
	 Section 3.3 Table C

MILESTONES for [***]

	 MILESTONE EVENT
	  	Payment
to Cellscript
	 [***]
	  	[***]
	 [***]
	  	[***]

 3.4    Earned Royalties. In partial consideration of the Sublicense, Company will
pay to Cellscript royalties on Net Sales of Licensed Products in the Sublicensed Fields of Use as stated below. 

3.4.1    Earned Royalties on Licensed Products in Field of Use A. In partial consideration of the Sublicense,
Company will pay to Cellscript a [***] percent ([***]%) royalty on Net Sales of Licensed Products by Company or its Affiliates or Third Party sublicensees for use in [***] during the Quarter. For the avoidance of doubt, if Company or any Affiliate
or Third Party sublicensee [***], then Company will pay to Cellscript [***] on all such Net Sales of Licensed Products for use in Field of Use A by Company or by said sublicensees. For clarity, Company and its Affiliates or Third Party sublicensees
shall not [***]. 
 3.4.2    Earned Royalties on Licensed Products for the In Vivo Field of Use
in Field of Use B. In partial consideration of the Sublicense, Company will pay to Cellscript a [***] percent ([***]%) royalty on Net Sales of Licensed Products in Field of Use B for all uses in the In Vivo Field of Use, including: [***]
during the Quarter. For the avoidance of doubt, if Company or its Affiliates or Third Party sublicensees grant sublicenses to sell Licensed Products for any such uses in Field of Use B, Company will pay to Cellscript a [***] percent [***] royalty on
Net Sales of all such Licensed Products sold by said sublicensees. 

  
 7 

 3.4.3    Royalty Reduction. If Company or an Affiliate or Third
Party sublicensee of Company is obligated to pay [***] (defined below) for a Licensed Product [***], then Company may deduct [***] percent ([***]%) of such [***] from any royalties on Net Sales in [***] due to Cellscript under Section 3.4.2 of
this Agreement, provided that: 
 (a)    On an ongoing basis and prior to reduction of any royalty on
Net Sales for a given calendar quarter, Company first provides [***]; and 
 (b)    In no event shall
royalties on Net Sales due to Cellscript in any reporting period be so reduced to less than [***] percent ([***]%) for Licensed Products for use in the In Vivo Field of Use in Field of Use B. 

“[***]” means any [***] that Company or an Affiliate or a Third Party sublicensee owes to one or more other parties pursuant to one
or more licenses for [***] that are determined to be [***] with respect to the manufacture, use or sale of any Licensed Product. 

3.5    Related Definitions. 

3.5.1    The term “Sale” means any bona fide transaction for which consideration is received or expected
by Company or its Affiliates or Third Party sublicensees for the sale, use, lease, transfer or other disposition of a Licensed Product to a Third Party. A Sale is deemed completed at the time that Company or an Affiliate or Third Party [***]. 

3.5.2    The term “Quarter” means each three-month period beginning on the first day of January, April,
July or October. 
 3.5.3    The term “Net Sales” means the consideration [***]. 

  
 8 

 3.5.4    The term “Qualifying Costs” means: [***]. 

3.6    Minimum Royalties. In partial consideration of the Sublicense, and only to the extent that [***], Company
will pay to Cellscript the amount, if any, by which the applicable minimum royalties listed for the respective Categories in the tables below exceed Company’s or its Affiliates’ or Third Party sublicensees’ actual earned royalties
under Section 3.4 for each Quarter after the first Sale of a Licensed Product in the Sublicensed Fields of Use in each said Category by Company or its Affiliates or Third Party sublicensees. For sake of clarity, the highest minimum royalty owed
by Company to Cellscript under this Agreement would be [***]. 
 Category 1 - Licensed Products in Field of Use A 

 

					
	 QUARTER:
	  	[***]	  	[***]
	 MINIMUM:
	  	[***]	  	[***]

 Category 2 - Licensed Products in Field of Use B 

For [***][***] 
  

					
	 QUARTER:
	  	[***]	  	[***]
	 MINIMUM:
	  	[***]	  	[***]

 Category 3 - Licensed Products in Field of Use B 

That [***] 
 For [***][***] 

 

					
	 QUARTER:
	  	[***]	  	[***]
	 MINIMUM:
	  	[***]	  	[***]

  
 9 

 4    REPORTS AND PAYMENTS 

4.1    Royalty Reports. Within [***] days after the end of each Quarter following the first Sale, Company will
deliver to Cellscript a report, [***], detailing the calculation of all royalties, fees and other payments due to Cellscript for such Quarter. The report will include, at a minimum, the following information for the Quarter, each listed by product,
by country: [***]. 
 4.2    Payments. Company will pay all royalties, fees and other payments due to Cellscript
under Sections 3.3, 3.4 and 3.6 within [***] days after the end of the Quarter in which the royalties, fees or other payments accrued. Cellscript agrees that it will pay all such amounts to mRNA RiboTherapeutics according to and within the time
periods required by the Cellscript Sublicense Agreement, and mRNA RiboTherapeutics will pay to Penn all royalties, fees and other payments due to Penn according to and within the time periods required by the Penn License Agreement. For clarity,
(a) only one royalty will be due with respect to the Sale of the same unit of Licensed Product and (b) royalties are payable hereunder only on Sales of Licensed Product for use in the Sublicensed Fields of Use, it being understood that
Company and its sublicensees have no right to sell Licensed Products in any Fields of Use except Sublicensed Fields of Use. 

4.3    Records. Company will maintain, and will cause its Affiliates and Third Party sublicensees to maintain,
complete and accurate books, records and related background information to verify Sales, Net Sales, and all of the royalties, fees, and other payments due or paid under this Agreement, as well as the various computations reported under
Section 4.1. The records for each Quarter will be maintained for at least [***] years after submission of the applicable report required for Section 4.1. 

4.4    Audit Rights. Upon [***], Company and its Affiliates and Third Party sublicensees will provide Penn and its
accountants (or Cellscript and its accountants in the event that Cellscript is Penn’s designated auditor) with access to [***] to conduct a review or audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under
this Agreement. Access will be made available: (a) during normal business hours; (b) in a manner reasonably designed to facilitate such accountant’s review or audit without unreasonable disruption to Company’s business; and
(c) no more than [***] during the Term (as defined below) and for a period of [***] thereafter. Company will promptly pay to Cellscript the amount of any underpayment determined by the review or audit, plus accrued interest. If the review or
audit determines that Company has underpaid any payment by [***] percent ([***]%) or more, then Company will also promptly pay the costs and expenses of the auditing party’s accountants in connection with the review or
audit.    In addition, once annual Sales of Licensed Products exceed [***]. 

4.5    Currency. All dollar amounts referred to in this Agreement are expressed in United States dollars. All
payments will be made in United States dollars. If Company receives payment from a sublicensee in a currency other than United States dollars for which a royalty or fee is owed under this Agreement, then (a) the payment will be converted into
United States dollars at the conversion rate for the foreign currency as published in the eastern edition of the Wall Street Journal as of the last business day of the Quarter in which the payment was received by Company, and (b) the conversion
computation will be documented by Company in the applicable report delivered to Cellscript under Section 4.1. 

  
 10 

 4.6    Place of Payment. All payments by Company to CELLSCRIPT,
LLC and will be made to the following addresses: 
  

			
	 By ACH/Wire:
	  	 By Check (direct mail):

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	
	 [***]
	  	 [***]

 4.7    Interest. All amounts that are not paid by Company when due will accrue
interest from the date due until paid at a rate equal to [***] percent ([***]%) per month (or the maximum allowed by law, if less). 

5    CONFIDENTIALITY AND USE OF NAMES 

5.1    Confidentiality. Each Party agrees that it will not, under this Agreement, provide to the other Party
or its affiliates any Confidential Information of such Party unless (i) such Party has first identified the general nature of such Confidential Information to such other Party in writing and such other Party has affirmatively agreed in writing
to receive such Confidential Information, or (ii) such other Party has specifically requested such Confidential Information in writing. For clarity, any such consent or request issued by email or other written electronic means shall satisfy the
foregoing “writing” requirements. Any Confidential Information disclosed by a Party to the other Party other than in accordance with this Section 5.1 will be deemed not to be Confidential Information of such Party. Notwithstanding the
foregoing, Cellscript is obligated to accept and treat as confidential any Confidential Information disclosed by Company in the reports or notices required by Sections 2.1, 2.3, 3.3, 3.4.3(a), 4.1, 4.4, 4.6 and 6.6, which information Company
agrees Cellscript may disclose to mRNA RiboTherapeutics or Penn without the prior written consent of Company. 

5.2    Confidential Information. Each Party (“Disclosing Party”) may disclose to the other Party
(“Receiving Party”), and Receiving Party may acquire during the course and conduct of activities under the Agreement, certain proprietary or confidential information of Disclosing Party in connection with this Agreement. The term
“Confidential Information” shall mean all ideas and information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, which are transferred, disclosed
or made available by Disclosing Party in accordance with Section 5.1. 

  
 11 

 5.3    Restrictions. During the Term and for [***] years
thereafter, Receiving Party shall keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information. Receiving Party shall not use Disclosing
Party’s Confidential Information except in connection with the performance of its obligations and exercise of its rights under this Agreement. Receiving Party has the right to disclose Disclosing Party’s Confidential Information without
Disclosing Party’s prior written consent, to the extent and only to the extent reasonably necessary, to Receiving Party’s affiliates and their employees, subcontractors, consultants or agents who have a need to know such Confidential
Information in order to perform Receiving Party’s obligations or exercise Receiving Party’s rights under this Agreement, provided said affiliates and their employees, subcontractors, consultants or agents are required to
comply with a written confidentiality agreement having restrictions on use and disclosure of Disclosing Party’s Confidential Information which are no less stringent than those in this Section 5.3 (other than with respect to the term of the
confidentiality obligations, which shall be at least [***] years from the date of disclosure). Receiving Party assumes responsibility for compliance with such restrictions by its affiliates and their employees, subcontractors, consultants or agents.

 5.4    Exceptions. Receiving Party’s obligation of nondisclosure and the limitations upon the right to
use the Disclosing Party’s Confidential Information shall not apply to the extent that Receiving Party can demonstrate, as evidenced by contemporaneous written records, that the Disclosing Party’s information: (i) was known to
Receiving Party or any of its affiliates prior to the time of disclosure; (ii) is or becomes public knowledge through no fault or omission of Receiving Party or any of its affiliates; (iii) is obtained by Receiving Party or any of its
affiliates from a Third Party under no obligation of confidentiality to Disclosing Party; (iv) has been independently developed by employees, subcontractors, consultants or agents of Receiving Party or any of its affiliates without the aid,
application or use of Disclosing Party’s Confidential Information or (v) is not Confidential Information under Section 5.1. 

5.5    Permitted Disclosures. Receiving Party may disclose Disclosing Party’s Confidential Information to the
extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 
 5.5.1    in order
to comply with applicable law (including any securities law or regulation or the rules of a securities exchange) or with a legal or administrative proceeding; 

5.5.2    in connection with prosecuting or defending litigation, regulatory approvals and other regulatory filings and
communications, and filing, prosecuting and enforcing patents in connection with Receiving Party’s rights and obligations pursuant to this Agreement; and 

5.5.3    in connection with exercising its rights hereunder, to its affiliates; in the case of Company as the Receiving
Party, to potential and future collaborators and sublicensees; in the case of Company or Cellscript as the Receiving Party, to permitted acquirers or assignees; and investment bankers, investors and lenders, except that Cellscript will obtain the
prior written consent of Company before disclosing any information disclosed to Cellscript pursuant to Sections 2.1, 2.3, 3.3, 3.4.3(a), 4.1, 4.4, 4.6 and 6.6; 

provided that (1) with respect to Sections 5.5.1 or 5.5.2, where reasonably possible, Receiving Party shall notify Disclosing
Party of Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality
of the information to be disclosed, and (2) with respect to Section 5.5.3, each of those named people 

  
 12 

 
and entities are required to comply with the restrictions on use and disclosure in Section 5.3 (other than investment bankers, investors and lenders, which must be bound prior to disclosure
by commercially reasonable obligations of confidentiality). 
 5.6    Terms of this Agreement. The Parties agree
that the terms of this Agreement shall be treated as Confidential Information of both Parties, and thus may be disclosed only as permitted by Section 5.5. Each Party agrees not to issue any press release or public statement disclosing
information relating to this Agreement or the terms hereof without the prior written consent of the other Party not to be unreasonably withheld. 

5.7    Use of Penn’s, Cellscript’s or Company’s Name. Company and its Affiliates, Third Party
sublicensees, employees, and agents are not granted any rights hereunder to use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, or their respective organizations, employees, students or
representatives, without the prior written consent of Penn. Except to the extent permitted pursuant to this Article 5, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or
any other trade name or trademark of the other Party for any Purpose, except as may be required by applicable law or regulation. 

6    TERM AND TERMINATION 

6.1    Term. This Agreement will commence on the Effective Date and terminate upon the expiration or abandonment of
the last patent to expire or become abandoned of the Patent Rights (the “Term”). 
 6.2    Early
Termination by Company. Company may terminate this Agreement at any time effective upon completion of each of the following conditions: (a) providing at least sixty (60) days prior written notice to Cellscript of such intention to terminate; (b)
ceasing to make, have made, use, import, offer for sale and sell all Licensed Products under the Sublicense; [***]. For clarity, Company may individually terminate either the Sublicense to Exhibit A-1 Patent
Rights or the Sublicense to Exhibit A-2 Patent Rights provided that each of the conditions stipulated in Section 6.2 is met with respect to the Patent Rights terminated from the Sublicense. [***] [***]

 6.3    Early Termination by Cellscript. Cellscript may, to the extent permissible by law, terminate this
Agreement if: (a) Company is more than [***] days late in paying to Cellscript any amounts owed under this Agreement and does not pay Cellscript in full, including accrued interest, within [***] days after receiving written notice of the breach
from Cellscript (a “Payment Default”); or (b) other than a Payment Default, Company materially breaches this Agreement and Company does not cure the breach within [***] days after receiving written notice of the breach from
Cellscript; or (c) Company causes or experiences a Trigger Event, [***]. It is understood that, with respect to both of (a) and (b), Company is also responsible for its Affiliates and Third Parties sublicensees. 

6.4    Trigger Event. The term “Trigger Event” means any of the following: (a) Company
(i) becomes insolvent, bankrupt or generally fails to pay its debts as such debts become due, (ii) is adjudicated insolvent or bankrupt, (iii) admits in writing its inability to pay its debts, (iv) suffers the appointment of a
custodian, receiver or trustee for its assets and, if appointed without its consent, not discharged within [***] days, (v) makes an assignment of its assets for the benefit of creditors, or (vi) suffers proceedings being instituted against
it under any law related to bankruptcy, insolvency, dissolution, liquidation or the reorganization, readjustment or release of multiple debtors and, if contested by it, not dismissed or stayed within [***] days; (b) the institution or
commencement by Company of any proceeding under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or release of multiple 

  
 13 

 
debtors; (c) the entering of any order for relief relating to any of the proceedings described in Section 6.4(a) or (b) above; (d) the calling by Company of a meeting of multiple
creditors with a view to arranging a composition of adjustment of its debts; (e) the act or failure to act by Company that results in its consent to, approval of, or acquiescence in any of the proceedings described in Section 6.4(a) - (d)
above; or (f) [***]. 
 6.5    Effect of Termination. 

6.5.1    Effect of Termination Except under Section 6.2. Upon the termination of this Agreement
prior to expiration of the Term for any reason except pursuant to Section 6.2: (a) the Sublicense to the Patent Rights and Exhibit D Patents will terminate; (b) [***] (c) Company will pay to Cellscript all amounts, including accrued interest,
owed to Cellscript under this Agreement through the date of termination, including royalties on Licensed Products invoiced or shipped through the date of termination and any sell off period permitted by Section 6.6, whether or not payment is
received prior to termination or expiration of the sell off period permitted by Section 6.6; (d) Company will, at Cellscript’s request, return to Cellscript all confidential information of Cellscript (if any) related to exploitation of
Patent Rights and Exhibit D Patents and [***]; (e) in the case of termination under Section 6.3, all duties of Cellscript and all rights (but not duties) of Company under this Agreement immediately terminate without further action required by
either Cellscript or Company; and (f) all outstanding Third Party sublicenses, to the extent each is not in default, will be assigned by Company to Cellscript, [***], and each Third Party sublicense agreement will remain in full force and
effect [***], but the duties and obligations of Cellscript under the [***] sublicense agreements will not be greater than the duties of Cellscript under this Agreement and the rights of Cellscript under the [***] sublicenses will not be less than
those of Cellscript under this Agreement, including [***]. Notwithstanding the foregoing, in the event the Cellscript Sublicense Agreement is terminated and said termination of the Cellscript Sublicense Agreement is not due to any act or omission of
Company or its Affiliates or Third Party sublicensees and, to the extent the Company is not in default under the Sublicense, Cellscript will assign this Agreement to mRNA RiboTherapeutics, such assignment will be accepted by mRNA RiboTherapeutics
and this Agreement and each of Company’s further sublicense agreements, to the extent each said further sublicense is not in default, will remain in full force and effect (including with respect to the sublicensed Exhibit A-1 Patent Rights and Exhibit A-2 Patent Rights and Exhibit D Patents), with mRNA RiboTherapeutics as the sublicensor to Company instead of Cellscript, but the duties and
obligations of mRNA RiboTherapeutics under the assigned Sublicense and the Company’s further sublicenses will not be greater than the duties of Cellscript under this Agreement, and the rights of mRNA RiboTherapeutics under the assigned
Sublicense and Company’s further sublicenses will not be less than the rights of Cellscript under this Agreement, [***]. 

6.5.2    Effect of Termination under Section 6.2. Upon the termination of this Agreement under
Section 6.2: (a) the Sublicense to Company and all further sublicenses to Affiliates and Third Parties terminate (except to the extent that said Third Party sublicenses [***] (b) [***]; (c) Company will pay to Cellscript all amounts, including
accrued interest, owed to Cellscript under this Agreement through the date of termination, including royalties on Licensed Products invoiced or shipped through the date of termination and any sell off period permitted by Section 6.6, whether or
not payment is received prior to termination or expiration of the sell off period permitted by Section 6.6, and (d) Company will, at Cellscript’s request, return to Cellscript all confidential information of Cellscript; and
(e) all outstanding sublicenses of Company to Third Parties and all outstanding sublicenses of Company’s Affiliates to Third Parties, to the extent each is not in default, will be assigned [***] to Cellscript [***], and each such assigned

  
 14 

 
sublicense agreement will remain in full force and effect [***], but the duties and obligations of Cellscript under the [***] sublicense agreements will not be greater than the duties and
obligations of Company under this Agreement, and the rights of Cellscript under the [***] sublicense agreements will not be less than the rights of Company under this Agreement, including [***], and Cellscript may, [***]. 

6.6    Inventory & Sell Off. Subject to the remainder of this Section 6.6, upon the
termination of this Agreement for any reason, Company will: (1) cause physical inventories to be taken [***] of: (a) all completed Licensed Products on hand under the control of Company and its Affiliates and Third Party sublicensees and
(b) such Licensed Products as are in the process of manufacture and any component parts on the date of termination of this Agreement; (2) deliver promptly to Cellscript a copy of said written inventory, [***]; (3) promptly remove, efface
or destroy or require or cause to be removed, effaced or destroyed all references to Penn and Cellscript from any advertising, labels, web sites or other materials used in the promotion of the business of Company or its Affiliates or Third Party
sublicensees; and (4) [***]. Subject to this Section 6.6, Company and its Affiliates and Third Party sublicensees may sell off its inventory of Licensed Products existing on the date of termination for a period of [***] months and pay
Cellscript royalties on Sales of such inventory within [***] days following the expiration of such [***] month period. Notwithstanding the foregoing: (i) Company’s obligations under this Section 6.6 will not apply to the Sublicense or
to Company’s sublicense agreements if the Sublicense is assigned to mRNA RiboTherapeutics pursuant to Section 6.5.1; and (ii) the obligations of each of Company’s sublicensees pursuant to this Section 6.6 will not apply to
Company’s or its Affiliates’ or Third Party sublicensees’ sublicense agreements that are assigned to Cellscript pursuant to Sections 6.5.1(f) or 6.5.2(e); and, (iii) Company’s and its Affiliates’ and Third Party
sublicensees’ obligations under this Section 6.6 will not apply with respect to any Licensed Product that is for use in a Field of Use for which Company (and its Affiliates or Third Party sublicensees) has a different sublicense agreement
[***]. 
 6.7    Survival. Company’s obligation to pay all amounts, including accrued interest, owed to
Cellscript under this Agreement will survive the termination of this Agreement for any reason. [***] will survive the termination of this Agreement in accordance with their respective terms. The Parties acknowledge and agree that the Sublicense is,
for the purposes of section 365(n) of the U.S. Bankruptcy Code, a license to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties intend that all payments under Article 3 of this Agreement
constitute “royalties” within the meaning of section 365(n) of the U.S. Bankruptcy Code. 
 7    PATENT PROSECUTION AND
MAINTENANCE 
 7.1    Patent Control for Patent Rights. [***] control the preparation, prosecution and
maintenance of the Patent Rights and the selection of patent counsel, subject to the remainder of this Section 7.1. For purposes of this Section 7.1, the word “maintenance” includes any interference negotiations, claims, or
proceedings, in any forum, [***]), a Third Party, or the United States Patent and Trademark Office or any foreign equivalent pertaining to Patent Rights, and any requests [***] that the United States Patent and Trademark Office or any foreign
equivalent reexamine or reissue any patent in the Patent Rights. Notwithstanding the foregoing, [***] will provide [***] and its counsel with reasonable opportunities to consult with [***] regarding prosecution and maintenance of Patent Rights. 

7.2    Patent Control for Exhibit D Patents. [***] control the preparation, prosecution and maintenance of the
Exhibit D Patents and the selection of patent counsel, subject to the 

  
 15 

 
remainder of this Section 7.2. For purposes of this Section 7.2, the word “maintenance” includes any interference negotiations, claims, or proceedings, in any forum, [***], a
Third Party, or the United States Patent and Trademark Office pertaining to Exhibit D Patents, and any requests [***] that the United States Patent and Trademark Office reexamine or reissue any patent in the Exhibit D Patents. Notwithstanding the
foregoing, [***] will provide [***] and its counsel with reasonable opportunities to consult with [***] regarding prosecution and maintenance of Exhibit D Patents. 

8    INFRINGEMENT 

8.1    Control. [***] 

8.2    Cooperation. In any litigation under this Article 8, each Party, at the reasonable request and sole
expense of the other Party, will provide reasonable cooperation to such other Party. This Article 8 will not be construed to require either Party to undertake any activities, including legal discovery, at the request of any Third Party, except
as may be required by lawful process of a court of competent jurisdiction. 
 9    REPRESENTATIONS, WARRANTIES, COVENANTS AND
DISCLAIMER OF WARRANTIES 
 9.1    Covenants of Cellscript. Cellscript covenants to Company that, during the
Term: 
 9.1.1    Cellscript will take all reasonable actions necessary to maintain Cellscript’s rights under the
Cellscript Sublicense Agreement and to the extent within its power, will ensure that the rights granted to Company herein are maintained. 

9.1.2    In the event of termination of the Cellscript Sublicense Agreement, this Agreement will be assigned to mRNA
RiboTherapeutics without any further action by the Parties, and the sublicenses granted hereunder, to the extent they are not in breach or default, will remain in full force and effect with respect to the sublicensed Exhibit A-1 Patent Rights, Exhibit A-2 Patent Rights and Exhibit D Patents. 

9.1.3    Cellscript will use diligent efforts not to breach the Cellscript Sublicense Agreement, and to the extent within
its legal power, will ensure that its sublicensed affiliates do not breach or cause a breach of any sublicense under the Cellscript Sublicense Agreement that would result in mRNA RiboTherapeutics having the right to terminate the Cellscript
Sublicense Agreement or Penn having the right to terminate the Penn License Agreement, and, in the event of any such breach, Cellscript will use diligent efforts to expeditiously cure (or cause to be cured) any such breach. 

9.1.4    Upon Cellscript learning of any breach of a sublicense agreement by any sublicensee of Cellscript or any of its
further sublicensees that would result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement or Penn having the right to terminate the Penn License Agreement, Cellscript will expeditiously take appropriate
actions to stop such act or omission, up to and including termination of the applicable sublicense, as stated in Section 1.5.4 of the Cellscript Sublicense Agreement. 

9.1.5    Cellscript will make all payments due under the Cellscript Sublicense Agreement and will make all required
disclosures to mRNA RiboTherapeutics in connection therewith, in each case in a timely manner in accordance with the terms thereof. 

  
 16 

 9.1.6    Promptly following Cellscript’s or any of its
affiliates’ receipt of any material written notice or correspondence pertaining to the Sublicense that would reasonably be expected to adversely affect Company’s rights under this Agreement, Cellscript will, to the extent permissible,
furnish a copy of such notice or correspondence to Company, provided that Cellscript may redact portions of any such notice or correspondence that do not relate to or impact Company’s rights hereunder. 

9.1.7    Cellscript will promptly notify Company if Cellscript receives a notice from mRNA RiboTherapeutics or Penn of
intent to terminate the Penn License Agreement. 
 9.1.8    Cellscript agrees that Cellscript and its affiliates will
not sue, bring an action against, or otherwise assert any claim against Company or its Affiliates or Third Party sublicensees or their successors in ownership (to which this Agreement or a sublicense under this Agreement is assigned according to
terms and conditions for assignment pursuant to Section 15.5 or Section 1.5.5 herein) for infringement of or misappropriation of any Patent Rights (as defined in Section 1.2) or Exhibit D Patents (as defined in Section 1.7) that
are used by Company or its Affiliates or Third Party sublicensees or their successors in ownership in the In Vivo Field of Use (as defined in Section 1.2) within Sublicensed Fields of Use. For clarity, the foregoing covenant [***]. For
further clarity, [***]. This covenant shall terminate with the termination of this Agreement unless the termination is: [***] (“Contested Termination”). In the event of a Contested Termination, this covenant shall continue
to run during the [***] days, and if a lawsuit is initiated, until said state or federal court enters a final decision from which no appeal has been or can be taken. 

9.1.9    Cellscript will not amend the Cellscript Sublicense Agreement in any manner that would negatively affect the
rights and/or obligations of the Company under this Agreement. Following execution of any amendment to the Cellscript Sublicense Agreement that pertains to or impacts Company or its rights hereunder, Cellscript agrees that it will provide a copy of
same to Company, except that Cellscript may redact portions of any such amendment that do not relate to or impact Company or its rights hereunder in any way. 

9.1.10    To the extent within its rights and legal power, Cellscript will not exercise any right to terminate the
Cellscript Sublicense Agreement in whole or in part. 
 9.1.11    [***] 

9.2    Covenants of mRNA RiboTherapeutics. mRNA RiboTherapeutics covenants to Company as follows: 

9.2.1    mRNA RiboTherapeutics will not terminate the Cellscript Sublicense Agreement without good and reasonable cause.

 9.2.2    In the event of termination of the Cellscript Sublicense Agreement, provided that Company did not cause said
termination of the Cellscript Sublicense Agreement and is not in breach or default under this Agreement, this Agreement will be assigned to mRNA RiboTherapeutics without any further action by Cellscript, mRNA RiboTherapeutics will accept such
assignment of this Agreement and this Agreement, including all of Company’s outstanding Third Party sublicenses thereunder, will remain in full force and effect with respect to the sublicensed Exhibit A-1
Patent Rights, Exhibit A-2 Patent Rights, with mRNA RiboTherapeutics as the sublicensor instead of Cellscript, but the duties and obligations of mRNA RiboTherapeutics under the assigned Agreement will not be
greater than the duties of Cellscript under this Agreement and the rights (including all financial consideration and other rights) of mRNA RiboTherapeutics under the assigned Agreement will not be less than those of Cellscript

  
 17 

 
under this Agreement, and mRNA RiboTherapeutics may, at its sole discretion, amend this Agreement to contain terms and conditions found in the Cellscript Sublicense Agreement. 

9.2.3    Upon mRNA RiboTherapeutics learning of any breach of a sublicense agreement by any sublicensee or any further
sublicensees thereof in any manner that would result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement or Penn having the right to terminate the Penn License Agreement, mRNA RiboTherapeutics will
expeditiously take appropriate actions to stop such act or omission, up to and including termination of the applicable sublicense. 

9.2.4    mRNA RiboTherapeutics will make all payments due under the Penn License Agreement and will make all required
disclosures to Penn in connection therewith, in each case in a timely manner in accordance with the terms thereof. 

9.2.5    Promptly following mRNA RiboTherapeutics’ or any of its affiliates’ receipt of any material written
notice or correspondence pertaining to the Company’ sublicense agreement from Cellscript that would reasonably be expected to adversely affect Company’s rights thereunder, mRNA RiboTherapeutics will, to the extent permissible, furnish a
copy of such notice or correspondence to Cellscript and to Company, provided that mRNA RiboTherapeutics, as applicable, may redact portions of any such notice or correspondence that do not relate to or impact Company’s rights. 

9.2.6    mRNA RiboTherapeutics will promptly notify Cellscript and Company if it receives a notice from Penn of intent to
terminate the Penn License Agreement. 
 9.2.7    mRNA RiboTherapeutics agrees that mRNA RiboTherapeutics and its
affiliates will not sue, bring an action against, or otherwise assert any claim against Company or its Affiliates or Third Party sublicensees or their successors in ownership (to which this Agreement or a sublicense under this Agreement is assigned
according to terms and conditions for assignment pursuant to Section 15.5 or Section 1.5.5 herein) for infringement of or misappropriation of any Patent Rights (as defined in Section 1.2) that are used by Company or its Affiliates or
Third Party sublicensees or their successors in ownership in the In Vivo Field of Use [***]. This covenant shall terminate with the termination of this Agreement unless the termination is a Contested Termination. In the event of a
Contested Termination, this covenant shall continue to run during the [***] days, and if a lawsuit is initiated, until said state or federal court enters a final decision from which no appeal has been or can be taken. 

9.2.8    mRNA RiboTherapeutics will not amend the Cellscript Sublicense Agreement in any manner that would negatively
affect the rights and/or obligations of the Company under this Agreement. 
 9.2.9    [***] 

9.3    Covenants of Company. Company covenants to Cellscript and to mRNA RiboTherapeutics that, during the Term:

 9.3.1    Upon Company learning of any breach of a sublicense agreement by any of its Affiliates or Third Party
sublicensees in any manner that would result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement or Penn having the right to terminate the Penn License Agreement, Company will [***]. 

9.3.2    Company will not breach this Agreement, and to the extent within its legal power, will ensure that its Affiliates
do not breach or cause breach of any sublicense under this Agreement, in any manner that would [***]. 

  
 18 

 9.3.3    Company will pay all payments due under this Agreement pursuant
to Article 3 and in accordance with the terms in Articles 3 and Section 4.2 and will provide all information, reports and notices required in accordance with Sections 2.1, 2.3, 3.3, 3.4.3(a), 4.1, 4.4 and 6.6 and in the form of the sample
report attached as Exhibit C, in each case in accordance with the time periods set forth therein. 
 9.3.4    Promptly
following Company’s or any of its Affiliates’ receipt of any material written notice or correspondence pertaining to the Sublicense that would reasonably be expected to adversely affect Cellscript’s rights or obligations under this
Agreement, Company will, to the extent permissible, furnish a copy of such notice or correspondence to Cellscript, provided that Company may redact portions of any such notice or correspondence that do not relate to or impact Cellscript ’s
rights hereunder. 
 9.3.5    Company will promptly notify Cellscript if Company receives [***]. 

9.3.6    [***] 

9.4    Representations and Warranties of Cellscript. As of the Effective Date, Cellscript, on behalf of itself and
its affiliates, hereby represents and warrants to Company that: 
 9.4.1    (a) either Cellscript or mRNA
RiboTherapeutics has provided Company with a copy of a true and correct copy of the Cellscript Sublicense Agreement (including all exhibits and amendments thereto), which has been redacted only with respect to the numerical values of the
compensation payable thereunder and certain terms and conditions that do not pertain to and that are immaterial to Company’s rights in the Sublicensed Fields of Use, (b) prior to the Effective Date, mRNA RiboTherapeutics has provided
Company with an opportunity to view a copy of the Cellscript Sublicense Agreement (including all exhibits and amendments thereto) which is true, correct and complete except for being redacted only with respect to the amounts paid or payable by
Cellscript to mRNA RiboTherapeutics for said sublicense and the milestones and other fees and royalties payable by Cellscript for the Ex Vivo Field of Use; (c) either Cellscript or mRNA RiboTherapeutics has provided Company with a true
and correct copy of the Penn License Agreement (including all exhibits and amendments thereto) which has been redacted only with respect to the numerical values of the compensation payable thereunder and certain terms and conditions that do not
pertain to and that are immaterial to Company’s rights in the Sublicensed Fields of Use or the fields of use sublicensed to Company under the mRNA RiboTherapeutics Sublicense Agreement, (d) prior to the Effective Date, mRNA
RiboTherapeutics has provided Company with an opportunity to view a true and correct and copy of the Penn License Agreement (including all exhibits and amendments thereto) which has been redacted only with respect to [***], (d) except for [***],
there is no other outstanding license, sublicense agreement, written or verbal, for Patent Rights in Field of Use B between Cellscript or mRNA RiboTherapeutics (or any affiliate thereof) on the one hand and Penn on the other hand, or between
Cellscript (or any affiliate thereof) and mRNA RiboTherapeutics (or any affiliate thereof). 
 9.4.2    (a) Neither
Cellscript nor any affiliate thereof has [***]; (b) except for (i) this Agreement to Company, (ii) the Cellscript Sublicense Agreement; (iii) the mRNA RiboTherapeutics Sublicense Agreement to Company, [***]; and (c) Cellscript
has not granted any liens or encumbrances in or to its rights in Patent Rights or the Cellscript Sublicense Agreement. 

  
 19 

 9.4.3    Cellscript has not breached or defaulted under any provision of
the Cellscript Sublicense Agreement in any material respect or received any written notice from mRNA RiboTherapeutics of any claims for indemnification pursuant thereto. 

9.4.4    To the knowledge of Cellscript, (a) there are no facts that would preclude Penn from having clear title to
the Patent Rights, (b) there are no pending or threatened litigations, interferences, reexaminations, oppositions or like procedures involving any such Patent Rights and (c) all of the issued patents within the Patent Rights are valid and
enforceable, are in full force and effect and have not lapsed, expired or otherwise terminated. 
 9.4.5    Cellscript
believes the terms and conditions of this Agreement are [***] consistent with the terms and conditions of the Cellscript Sublicense and the Penn License Agreement; 

9.4.6    Cellscript has not received any written notice of any claim by any person or entity challenging the sublicense
rights of Cellscript or the validity or enforceability of the Patent Rights. 
 9.4.7    [***] 

9.4.8    Cellscript believes that the representations and warranties of Cellscript in this Agreement, do not, taken as a
whole, (i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading.
Cellscript has not knowingly withheld any information with respect to the Cellscript Sublicense Agreement, the Penn License Agreement or the Patent Rights that would reasonably be expected to be material to Company’s decision to enter into this
Agreement. 
 9.5    Representations and Warranties of mRNA RiboTherapeutics. As of the Effective Date, mRNA
RiboTherapeutics, on behalf of itself and its affiliates, hereby represents and warrants to Company that: 

9.5.1    (a) either Cellscript or mRNA RiboTherapeutics has provided Company with a copy of a true and correct copy of the
Cellscript Sublicense Agreement (including all exhibits and amendments thereto), which has been redacted with respect to the numerical values of the compensation payable thereunder and certain terms and conditions that do not pertain to and that are
immaterial to Company’s rights in the Sublicensed Fields of Use, (b) prior to the Effective Date, either mRNA RiboTherapeutics or Cellscript has provided Company with an opportunity to view a copy of the Cellscript Sublicense Agreement
(including all exhibits and amendments thereto) which is true, correct and complete except for being redacted only with respect to the amounts paid or payable by Cellscript to mRNA RiboTherapeutics for said sublicense and the milestones and other
fees and royalties payable by Cellscript for the Ex Vivo Field of Use; (c) either Cellscript or mRNA RiboTherapeutics has provided Company with a true, correct and complete copy of the Penn License Agreement (including all exhibits and
amendments thereto), which has been redacted with respect to the numerical values of the compensation payable thereunder and certain terms and conditions that do not pertain to and that are immaterial to Company’s rights in the Sublicensed
Fields of Use or the fields of use sublicensed to Company under the mRNA RiboTherapeutics Sublicense Agreement, (d) prior to the Effective Date, mRNA RiboTherapeutics has provided Company with an opportunity to view a true and correct copy of
the Penn License Agreement (including all exhibits and amendments thereto) which has been redacted only with respect to [***], there are no other license, sublicense or other agreements, written or verbal, relating to the Patent Rights between
Cellscript or mRNA 

  
 20 

 
RiboTherapeutics (or any affiliate thereof) on the one hand and Penn on the other hand, or between Cellscript (or any affiliate thereof) and mRNA RiboTherapeutics (or any affiliate thereof). 

9.5.2    (a) Neither mRNA RiboTherapeutics nor any affiliate thereof has [***]; (b) except for (i) the Cellscript
Sublicense Agreement; (ii) this Agreement to Company, (iii) the mRNA RiboTherapeutics Sublicense Agreement to Company, (iv) [***], and (v) [***]; and (c) neither mRNA RiboTherapeutics nor any affiliate thereof has granted any liens or
encumbrances in or to its rights in Patent Rights or the Cellscript Sublicense Agreement. 
 9.5.3    Cellscript has not
breached or defaulted under any provision of the Cellscript Sublicense Agreement in any material respect or received any written notice from mRNA RiboTherapeutics of any claims for indemnification pursuant thereto and mRNA RiboTherapeutics
has not breached or defaulted under any provision of the Penn License Agreement in any material respect or received any written notice from Penn of any claims for indemnification pursuant thereto. 

9.5.4    To the knowledge of mRNA RiboTherapeutics, (a) there are no facts that would preclude Penn from having clear
title to the Patent Rights, (b) there are no pending or threatened litigations, interferences, reexaminations, oppositions or like procedures involving any such Patent Rights and (c) all of the issued patents within the Patent Rights are
valid and enforceable, are in full force and effect and have not lapsed, expired or otherwise terminated. 

9.5.5    mRNA RiboTherapeutics believes the terms and conditions of this Agreement are [***] consistent with the terms and
conditions of the Cellscript Sublicense Agreement and the Penn License Agreement. 
 9.5.6    mRNA RiboTherapeutics has
not received, any written notice of any claim by any person or entity challenging the sublicense rights of Cellscript or the validity or enforceability of the Patent Rights. 

9.5.7    [***] 

9.5.8    mRNA RiboTherapeutics believes that the representations and warranties of mRNA RiboTherapeutics in this
Agreement, do not, taken as a whole, (i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they
were made, not misleading. mRNA RiboTherapeutics has not knowingly withheld any information with respect to the Cellscript Sublicense Agreement, the Penn License Agreement or the Patent Rights that would reasonably be expected to be material
to Company’s decision to enter into this Agreement. 
 9.6    Representations and Warranties of
Company. Company, on behalf of itself and its affiliates, hereby represents and warrants to Cellscript and to mRNA RiboTherapeutics that, as of the Effective Date:  

9.6.1    Company is duly organized and validly existing under the laws of the jurisdiction of its incorporation and has
full corporate power and authority to enter into this Agreement. 
 9.6.2    Company is in good standing with all
relevant governmental authorities. 
 9.6.3    Company has taken all corporate actions necessary to authorize the
execution and delivery of this Agreement and the performance of its obligations under this Agreement. 

  
 21 

 9.6.4    The performance of its obligations under this Agreement do not
conflict with or constitute a default under its charter documents, any contractual obligation of Company or any court order. 

9.6.5    [***] 

9.6.6    [***] 

9.6.7    Company has read the copy of the Penn License Agreement (including all exhibits and amendments thereto) that was
provided to Company by mRNA RiboTherapeutics or Cellscript. 
 9.6.8    Company has read the redacted copy of the
Cellscript Sublicense (including all exhibits and amendments thereto) that was provided to Company by Cellscript or mRNA RiboTherapeutics. 

9.6.9    Company believes that the representations and warranties of Company in this Agreement, do not, taken as a whole,
(i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading. Company has not
knowingly withheld any information with respect to the any of Company’s above statements that would reasonably be expected to be material to Cellscript’s decision to enter into this Agreement. 

9.7    Disclaimer of Warranties. EXCEPT AS SPECIFICALLY SET FORTH IN THIS ARTICLE 9, NO PARTY MAKES ANY
REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS OR SUFFICIENCY OF PATENT RIGHTS OR EXHIBIT D PATENTS FOR A PARTICULAR PURPOSE, APPLICATION OR USE,
NON-INFRINGEMENT, OR ANY OTHER STATUTORY WARRANTY. 
 10    ADDITIONAL TERMS REGARDING
SUBLICENSING 
 10.1    Purpose of this Article. This Article 10 sets forth terms and conditions for further
sublicensing by Primary Sublicensors in the Human In Vivo Therapeutics Field, wherein, for the purposes of this Article 10: 
  

	 	(a)	 “sublicensing” herein means any grant of a sublicense, covenant not to sue, or option for
current or future rights under Patent Rights, and the noun “sublicense” herein means a document that grants such sublicense, covenant not to sue, or option for current or future rights under Patent Rights; 

 

	 	(b)	 “Primary Sublicensors” herein means (i) mRNA RiboTherapeutics, (ii) Cellscript, and
(iii) any affiliate of (i) or (ii) that is granted a sublicense in the Human In Vivo Therapeutics Field; and 

  

	 	(c)	 “[***]” herein means any or all therapeutic and prophylactic use(s) in [***].

 For clarity and the absence of doubt, Article 10 shall not be interpreted in any way so as to limit, restrict or impose
any terms or conditions on Primary Sublicensors’ rights to grant sublicenses under Patent Rights to any party at any time for any Field of Use other than the Human In Vivo Therapeutics Field. 

  
 22 

 10.2    Human In Vivo Therapeutics Field
Sublicenses. Subject to the rights of the Primary Sublicensors and their respective owners under Section 10.4, Cellscript, mRNA RiboTherapeutics and Company agree that, from the Effective Date until [***], mRNA RiboTherapeutics and
Cellscript will not grant and will ensure that other Primary Sublicensors will not grant Human In Vivo Therapeutics Field Sublicenses[***]. 

“Human In Vivo Therapeutics Field Sublicense” means a sublicense to make, have made, use, import,
offer for sale, sell and/or have sold any number of products [***] for the Human In Vivo Therapeutics Field, [***]. 

10.3    Product Sublicenses. Subject to the rights of the Primary Sublicensors and their respective owners under
Section 10.4, Cellscript, mRNA RiboTherapeutics and Company agree that, from the Effective Date until [***], Cellscript and mRNA RiboTherapeutics will (and will ensure that the other Primary Sublicensors will): 

(a)    grant Product Sublicenses only to [***], 

wherein “Product Sublicenses” herein mean sublicenses under Patent Rights to research, develop, manufacture and/or
commercialize specific products [***], for a therapeutic or prophylactic use in humans in the In Vivo Field of Use, and 
 wherein
“[***]” herein means [***]: 
  

	 	(i)	 [***] 

  

	 	(ii)	 [***] 

  

	 	(iii)	 [***] 

(b)    only grant [***] Sublicenses for [***] 

(c)    except as set forth in Sections 10.2 and 10.3, not otherwise grant sublicenses under the Patent Rights to research,
develop, manufacture and/or commercialize [***] [***]. 
 10.4    Sale of a Primary Sublicensor. Company
understands and agrees that the owners of each of mRNA RiboTherapeutics and Cellscript shall have the right to sell all or any part of the outstanding stock or ownership interest or the business or the assets thereof, as applicable, of mRNA
RiboTherapeutics and/or Cellscript [***] at any time and without any conditions pursuant to this Agreement other than the requirements under Section 15.5, 

except that, as a condition to any such sale occurring prior to [***]: 

(a)    the owners of each of mRNA RiboTherapeutics and Cellscript [***] sell mRNA RiboTherapeutics or Cellscript to [***];
and 
 (b)    without in any way negating or ceding or giving up any of their current rights to sell all or any part of
the stock, ownership interest, business or assets of mRNA RiboTherapeutics and/or Cellscript or to discuss any such sale with any potential purchaser at any time, including from the Effective Date of this Agreement [***], the owners of mRNA
RiboTherapeutics and Cellscript agree not to [***] prior to [***], 
 wherein “[***]” herein means [***]; and 

for the avoidance of doubt, Company agrees that this Section 10.4(a) shall not be interpreted so as to prohibit the owners of mRNA
RiboTherapeutics and/or Cellscript from [***]; 
 (c)    the purchaser of mRNA RiboTherapeutics or Cellscript,
respectively, will pay [***]; 

  
 23 

 (d)    on the effective date of any such sale of [***], the purchased
company (whether mRNA RiboTherapeutics or Cellscript) and the purchaser and their assignees and successors in ownership thereof shall [***]: 
  

	 	(i)	 grant [***] Sublicenses to affiliates and Third Parties [***], and 

 

	 	(ii)	 grant [***] Sublicenses to affiliates and any Third Parties to research, develop, manufacture and/or
commercialize any number of products [***] without being subject to any of the restrictions, limitations or requirements that the sublicensee is [***] as is required of the Primary Sublicensors in Section 10.3; and 

(d)    on the effective date of any such sale of more than fifty percent (50%) of the outstanding stock or ownership
interest or all of the business or assets of mRNA RiboTherapeutics or Cellscript [***], all of the rights of the Primary Sublicensors to grant Product Sublicenses pursuant to Section 10.3 shall remain only with the Primary Sublicensors for
which their stock, ownership interest, business and assets were not sold. 
 [***] 

10.5    From [***], Primary Sublicensors and any owners, assignees or successors in ownership thereof shall have the right
to grant [***] of [***] Sublicense(s) to any parties without any conditions (other than those imposed by the Penn License Agreement or the Cellscript Sublicense) and to grant any number of Product Sublicenses or any other sublicenses of any kind
under Patent Rights to any parties without any limitations or restrictions or requirements whatsoever under this Article 10. 

11    LIMITATION OF LIABILITY; DISCLAIMER. 

11.1    Limitation of Liability. CELLSCRIPT, mRNA RIBOTHERAPEUTICS AND PENN WILL NOT BE LIABLE TO COMPANY, ITS
AFFILIATES, SUBLICENSEES, SUCCESSORS OR ASSIGNS, OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM: ARISING FROM COMPANY’S USE OF THE PATENT RIGHTS, EXHIBIT D PATENTS, LICENSED PRODUCTS OR ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT; OR
ARISING FROM THE COMPANY’S, COMPANY’S AFFILIATES’ OR COMPANY’S SUBLICENSEES’ DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NONE OF CELLSCRIPT,
mRNA RIBOTHERAPEUTICS, PENN, OR COMPANY WILL BE LIABLE TO THE OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH PARTY HAS BEEN INFORMED OR SHOULD
HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED THAT THIS SECTION 11.1 WILL NOT APPLY: (a) TO A PARTY’S INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER ARTICLE 12 OR ARTICLE 13; (b) IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL
MISCONDUCT BY A PARTY OR ITS AFFILIATES; OR (c) WITH RESPECT TO A PARTY’S LIABILITY FOR BREACH OF ARTICLE 5 or 10. 

11.2    Disclaimer. THE PATENT RIGHTS, EXHIBIT D PATENTS, LICENSED PRODUCTS AND ANY OTHER TECHNOLOGY LICENSED UNDER
THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NONE OF CELLSCRIPT, mRNA RIBOTHERAPEUTICS, PENN, OR COMPANY MAKE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR

  
 24 

 
IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY,
NON-INFRINGEMENT, VALIDITY OR TITLE. 
 12    PENN INDEMNIFICATION 

12.1    Indemnification. Company will defend, indemnify, and hold harmless each Penn Indemnified Party from and
against any and all Penn Liabilities with respect to an Indemnification Event. The term “Penn Indemnified Party” means each of Penn and its trustees, officers, faculty, students, employees, contractors, and agents. For clarity,
Cellscript is not a Penn Indemnified Party. The term “Penn Liabilities” means all damages, awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens,
losses, lost profits and expenses (including, but not limited to, court costs, interest and reasonable fees of attorneys, accountants and other experts) that are incurred by a Penn Indemnified Party or awarded or otherwise required to be paid to
Third Parties by a Penn Indemnified Party. The term “Indemnification Event” means any Claim against one or more Penn Indemnified Parties arising out of or resulting from: [***]. The term “Claim” in
this Article 12 means any charges, complaints, actions, suits, proceedings, hearings, investigations, claims or demands. 

12.2    Reimbursement of Costs. Company will pay directly all Penn Liabilities incurred for defense or negotiation
of any Claim or will reimburse Penn for all documented Penn Liabilities incident to the defense or negotiation of any Claim within [***] days after Company’s receipt of invoices for such fees, expenses and charges. 

12.3    Control of Litigation. Company controls any litigation or potential litigation involving the defense of any
Claim, including the selection of counsel, with input from Penn. Penn reserves the right to protect its interest in defending against any Claim by selecting its own counsel, with any attorneys’ fees and litigation expenses paid for by Company,
pursuant to Sections 12.1 and 12.2. 
 12.4    Other Provisions. Company will not settle or compromise any Claim
giving rise to Penn Liabilities in any manner that imposes any restrictions or obligations on Penn or grants any rights to the Patent Rights, Exhibit D Patents or the Licensed Products without Penn’s prior written consent. If Company fails or
declines to assume the defense of any Claim within [***] days after notice of the Claim, or fails to reimburse a Penn Indemnified Party for any Penn Liabilities pursuant to Sections 12.1 and 12.2 within the [***] day time period set forth in
Section 12.2, then Penn may assume the defense of such Claim for the account and at the risk of Company, and any Penn Liabilities related to such Claim will be conclusively deemed a liability of Company. The indemnification rights of the Penn
Indemnified Parties under this Article 12 are in addition to all other rights that a Penn Indemnified Party may have at law, in equity or otherwise. 

  
 25 

 13    OTHER INDEMNIFICATION 

13.1     Indemnification by Company. Company will indemnify, defend and hold harmless Cellscript and its affiliates,
and its or their respective directors, officers, employees and agents (“Cellscript Indemnified Parties”), from and against any and all liabilities, damages, losses, costs and expenses including the reasonable fees of attorneys
(collectively “Losses”) arising out of or resulting from any and all Third Party suits, claims, actions, proceedings, payment obligations or demands (“Claims” in this Article 13) to the extent based upon:

 13.1.1     [***] 

13.1.2     [***] 

13.1.3     [***] 

except, in each case above, to the extent such Claim arose out of or resulted from or is attributable to any acts or omissions of Cellscript
or its directors, officers, employees and agents, or other circumstances for which Cellscript has an indemnity obligation pursuant to Section 13.2 below. 

13.2    Indemnification by Cellscript. Cellscript will indemnify, defend and hold harmless Company and its
affiliates, and its or their respective directors, officers, employees and agents (“Company Indemnified Parties”), from and against any and all Losses arising out of or resulting from any and all Claims to the extent based upon:

 13.2.1    [***] 

13.2.2    [***] 

except, in each case above, to the extent such Claim arose out of or resulted from or is attributable to any acts or omissions of Company or
its affiliates or Third Party sublicensees or contractors and its or their respective directors, officers, employees and agents or other circumstances for which Company has an indemnity obligation pursuant to Section 13.1 above. 

13.3    Procedure. If an Indemnified Party entitled to indemnification under Sections 13.1 or 13.2 seeks such
indemnification (wherein “Indemnified Party” in this Article 13 means a “Company Indemnified Party” and/or an “Cellscript Indemnified Party”), such Indemnified Party will: 

(i)    inform the indemnifying Party in writing of a Claim as soon as reasonably practicable after such Indemnified Party
receives notice of such Claim; 
 (ii)    permit the indemnifying Party to assume direction and control of the defense
of the Claim (including the sole right to settle such Claim at the sole discretion of the indemnifying Party, provided that (a) such settlement or compromise does not admit any fault or negligence on the part of the Indemnified Party, or
impose any obligation on, or otherwise materially adversely affect, the Indemnified Party or other Party and (b) the indemnifying Party first obtains the written consent of the Indemnified Party with respect to such settlement, which consent
will not be unreasonably withheld); 
 (iii)    cooperate as reasonably requested (at the expense of the indemnifying
Party) in the defense of the Claim; and 
 (iv)    undertake reasonable steps to mitigate any Losses with respect to the
Claim. 
 Notwithstanding anything in this Agreement to the contrary, the indemnifying Party will have no liability under Sections 13.1 or
13.2, as the case may be, for Claims settled or compromised by the Indemnified Party without the indemnifying Party’s prior written consent. 

14    INSURANCE 

14.1    Coverages. Company will procure and maintain insurance or self-insurance that covers the following minimum
liability amounts with respect to personal injury, bodily injury and property damage arising out of Company’s performance under this Agreement: (a) during the Term, comprehensive general liability, including broad form and contractual
liability, in a 

  
 26 

 
minimum amount of $[***] combined single limit per occurrence and in the aggregate; (b) prior to the commencement of clinical trials involving Licensed Products, clinical trials a minimum amount
of $[***] combined single limit per occurrence and in the aggregate; and (c) prior to the Sale of the first Licensed Product, product liability a minimum amount of $[***] combined single limit per occurrence and in the aggregate. Penn and
Cellscript may review periodically the adequacy of the minimum amounts of insurance or self-insurance for each liability coverage area required by this Section 14.1, and Penn and Cellscript reserve the right to request Company to adjust the
limits accordingly to the extent existing limits are not commercially reasonable. The required minimum amounts of insurance or self-insurance do not constitute a limitation on Company’s liability or indemnification obligations to Penn or
Cellscript under this Agreement. 
 15    ADDITIONAL PROVISIONS 

15.1    Independent Contractors. The Parties are independent contractors. Nothing contained in this Agreement is
intended to create an agency, partnership or joint venture between the Parties. At no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party. 

15.2    No Discrimination. Company will not discriminate against any employee or applicant for employment because
of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status. 

15.3    Compliance with Laws. Company must comply with all prevailing laws, rules and regulations that apply to its
activities or obligations under this Agreement. For example, Company will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of
the United States government and/or written assurances by Company that Company will not export data or commodities to certain foreign countries without prior approval of the agency. Penn and Cellscript do not represent that no license is required,
or that, if required, the license will issue. 
 15.4    Modification, Waiver & Remedies.
This Agreement may only be modified by a written amendment that is executed by an authorized representative of each Party. Any waiver must be express and in writing. No waiver by either Party of a breach by the other Party will constitute a waiver
of any different or succeeding breach. Unless otherwise specified, all remedies are cumulative. 

15.5    Assignment. This Agreement may not be assigned (by operation of law or otherwise) by either Party without
the prior written consent of the other Party (which consent will not be unreasonably withheld); except that, either Party may assign this Agreement without such consent to an affiliate or to a Third Party successor that purchases greater than
fifty percent (>50%) of the outstanding stock or ownership interest or all or substantially all of such Party’s business or assets to which this Agreement relates, whether by sale of shares or ownership interest, merger, consolidation, sale
of assets or otherwise, provided that, prior to said transfer, the intended assignee agrees in writing to be legally bound by this Agreement in the place and stead of the assignor and provides the
non-assigning Party with a copy of said assignee’s written undertaking. Neither Party will grant a security interest in the Sublicense or this Agreement during the Term. Any prohibited assignment or
security interest in contravention of the foregoing will be null and void. The rights and obligations of the Parties under this Agreement will be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the
name of a Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Section 15.5. 

  
 27 

 15.6    Notices. Any notice or other required communication
(each, a “Notice”) must be in writing, addressed to the Party’s respective Notice Address listed on the signature page, and delivered: (a) personally, with signed receipt; (b) by certified mail, postage prepaid,
return receipt requested; (c) by recognized overnight courier service, charges prepaid; or (d) by facsimile. A Notice will be deemed received: if delivered personally, on the date of delivery; if mailed, five (5) days after deposit in
the United States mail; if sent via courier, one (1) business day after deposit with the courier service; or if sent via facsimile, upon receipt of confirmation of transmission provided that a confirming copy of such Notice is sent by certified
mail, postage prepaid, return receipt requested. 
 15.7    Severability & Reformation. If
any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable provision will be
automatically revised to be a valid or enforceable provision that comes as close as permitted by law to the Parties’ original intent. 

15.8    Headings & Counterparts. The headings of the articles and sections included in this
Agreement are inserted for convenience only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be executed in one or more counterparts, each of which when executed and delivered by facsimile,
electronic transmission, or by mail delivery, will be an original and all of which shall constitute one and the same instrument. 

15.9    Governing Law. This Agreement will be governed in accordance with the laws of the Commonwealth of
Pennsylvania, without giving effect to the conflict of law provisions of any jurisdiction. 
 15.10    Dispute
Resolution. If a dispute arises between the Parties concerning any right or duty under this Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute. If the Parties are unable to resolve the dispute
amicably, then the Parties will submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania with respect to all disputes arising under this Agreement. Notwithstanding anything
herein to the contrary, in the event of an actual or threatened breach of this Agreement, the aggrieved Party may seek provisional equitable relief (including restraining orders, specific performance or other injunctive relief) in any court of
competent jurisdiction to protect the interests of such Party. 
 15.11    Further Assurance. Each Party shall
duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this
Agreement. 
 15.12    Interpretation. Except where the context otherwise requires, wherever used, the singular
shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and
in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein shall mean including, without limiting the generality of any

  
 28 

 
description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against
either Party hereto. 
 15.13    Condition Precedent to Execution of this Agreement. The Parties understand and
agree that each Party’s willingness to enter into this Agreement is contingent upon the execution of both this Agreement and the mRNA RiboTherapeutics Sublicense Agreement ([***]), and, as such, the Parties’ willingness to enter into this
Agreement is conditioned upon the execution of the mRNA RiboTherapeutics Sublicense Agreement concurrently with this Agreement. 

15.14    Entire Agreement. This Agreement and the mRNA RiboTherapeutics Sublicense Agreement set forth the
complete, final and only agreements with respect to the subject matter hereof and supersede all other agreements and understandings between the Parties with respect to the subject matter hereof. The Parties acknowledge and agree that this Agreement
and the mRNA RiboTherapeutics Sublicense Agreement are separate and distinct agreements and there will be no “cross default” with respect to this Agreement and the mRNA RiboTherapeutics Sublicense Agreement. 

[Remainder of Page Intentionally Left Blank] 

  
 29 

 Each Party has caused this Agreement to be executed by its duly authorized representative. 

 

									
	CELLSCRIPT, LLC	 		 	MODERNATX, INC
					
	By:	 	/s/ Gary A. Dahl, Ph.D.	 		 	By:	 	/s/ Stephen Hoge, M.D.
	Name:	 	Gary A. Dahl, Ph.D.	 		 	Name:	 	Stephen Hoge, M.D.
	Title:	 	President	 		 	Title:	 	President

  

									
	Address:	 	CELLSCRIPT, LLC	 		 	MODERNATX, INC.
		 	726 Post Road	 		 	320 Bent Street
		 	Madison, WI 53713	 		 	Cambridge, MA 02141

 mRNA RIBOTHERAPEUTICS, INC., 

which is executing this Agreement solely 
 with respect to the
following provisions: 
  

	 	•	 	 Section 6.5.1, solely with respect to acceptance of sublicense agreements assigned by Cellscript;

  

	 	•	 	 Section 9.2, including 9.2.1 through 9.2.9; 

 

	 	•	 	 Section 9.5, including 9.5.1 through 9.5.8; and 

 

	 	•	 	 Article 10. 

  

			
	By:	 	/s/ Gary A. Dahl, Ph.D.
	Name:	 	Gary A. Dahl, Ph.D.
	Title:	 	President

  
 30 

 EXHIBIT INDEX 

 

			
		
	Exhibit A	  	Patents and Patent Applications in Patent Rights
		
	Exhibit B	  	Sublicense Disclosure Report
		
	Exhibit C	  	Form of Royalty Report
		
	Exhibit D	  	Cellscript’s Exhibit D Patents

  
 31 

 EXHIBIT A – Patents and Patent Applications in Patent Rights 

EXHIBIT A-1 [***] 
  

									
	 Patent

Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Title

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]

  
 32 

 EXHIBIT A – Patents and Patent Applications in Patent Rights 

(continued) 
 EXHIBIT A-2 [***] 
  

									
	 Patent

Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Title

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  	[***]	  		  	[***]

  
 33 

 Exhibit B 

Sublicense Disclosure Report 

[***] 

  
 34 

 EXHIBIT C – Format of Royalty Report 

[***] 

  
 35 

 Exhibit D 

Exhibit D Patents Sublicensed to Company under Section 1.7. 

 

									
	 Patent Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Title

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]

  
 36

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]